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Sammendrag 
Bakgrunn: Polycystisk ovariesyndrom (PCOS) er en kompleks endokrin forstyrrelse 
hos kvinner og har viktige helsekonsekvenser. Pasienter med PCOS har høy 
forekomst av risikofaktorer for kardiovaskulær sykdom, høyere risiko for utvikling av 
diabetes type 2 og opp til 30-70 % av PCOS pasientene er overvektige. Oksidativ 
stress kan ha en sentral rolle i utvikling av alle disse sykdommene og det ble vist at 
økt oksidativ stress og nedsatt antioksidant kapasitet kan gi økt risiko for 
kardiovaskulær sykdom i kvinner med PCOS. Basert på foreliggende kunnskap, riktig 
kost kan korrigere hormonell og metabolsk balanse, og redusere risikoen for diabetes 
type 2. Individualisert vektnedgang kunne ha en viktig plass i livsstil intervensjon i 
PCOS.  
Flere studier har også foreslått en link mellom spiseforstyrrelser, spesielt bulimia 
nervosa, og PCOS. Hensikten med denne studien, derfor, var å sammenligne kost og 
antioksidant konsentrasjoner mellom kvinner med PCOS og BMI-matched kontroller 
for å få kunnskap om mulige kost intervensjoner i denne pasient gruppen og å 
sammenligne spise atferden mellom gruppene.  
Vi studerte også assosiasjoner mellom plasma antioksidanter og serum ferritin nivåer, 
og antropometriske målinger.  
Sted: Stavanger Universitetssykehus    
Deltakere: Til sammen 25 kvinner diagnostisert med PCOS og 24 BMI-matched 
friske kvinner.  
Metode: Deltakernes matinntak ble registrert ved bruk av prekodet matdagbok. 
Deltakernes spise atferd var studert ved bruk av to spørreskjema (binge eating scale 
(BES) og three-factor eating questionnaire (TFEQ).   
Resultater: Det ble ikke påvist statistisk signifikant forskjell i mikro- og 
makronæring inntak mellom gruppene. Begge gruppene underapporterte deres 
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energiinntak og hadde en kost med høy energiandel fra mettet fett og lav innhold av 
fiber, enkelte vitaminer (som folat, tiamin, riboflavin og vitamin D) og jern. Det ble 
ikke påvist statistisk signifikant forskjell i plasma antioksidant, vitamin og jern 
konsentrasjoner mellom gruppene. Kvinnene med PCOS hadde høyere serum ferritin 
nivåer men forskjellen var ikke statistisk signifikant.   
Både BMI og mageomkrets korrelerte signifikant og negativ med plasma 
konsentrasjoner av flere antioksidanter som lycopen, xanthophyll, beta-karoten og 
vitamin C. Sterk positiv korrelasjon mellom mageomkrets, BMI og serum ferritin 
nivåer var påvist i PCOS gruppen men ikke i kontroll gruppen.   
Kvinnene med PCOS rapporterte høyere BES and TFEQ score, men forskjellen var 
ikke statistisk signifikant.  
Konklusjon: Når matched i forhold til BMI, ble det ikke påvist signifikant forskjeller 
i kost og plasma antioksidant og vitamin nivåer mellom kvinner med PCOS 
rapporterte og friske kontroller. Høyere BMI var assosiert med lavere nivåer av flere 
antioksidanter og med emosjonell spising.   
Et balansert kosthold bør anbefales til kvinner med PCOS, spesielt i forhold til de 
negative helsekonsekvensene disse pasientene er utsatt for. Man bør ha ekstra fokus 
på kvinner med høy BMI.  
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Summary  
Background: PCOS is a complex endocrine disease with important health 
implications. PCOS patients have a higher prevalence of cardiovascular risk factors 
and higher risk for type 2 diabetes and up to 30-70 % of women affected with PCOS 
are obese. Oxidative stress may play a central role in the pathophysiology of these 
disorders and it has been shown that increased oxidative stress and decreased 
antioxidant capacity may contribute to the increased risk of cardiovascular disease in 
women with PCOS. Evidence suggest that diet not only ameliorate many of the 
features of the metabolic syndrome present in these women, but also could reduce risk 
for type 2 diabetes mellitus. Weight loss and maintenance may play an important role 
to lifestyle intervention in PCOS. Furthermore, a link between PCOS and eating 
disorders, specifically bulimia nervosa, was suggested by several studies.   
Thus, the aim of this study was to compare the diet and antioxidant levels of women 
with PCOS to matched controls, in order to understand the potential of dietary 
intervention in this group of patients and further to compare eating behaviour in the 
two groups. We also studied the association between plasma antioxidants and ferritin 
levels with anthropometric measures. 
Setting : Stavanger University Hospital. 
Subjects: A total of 25 women diagnosed with PCOS and 24 BMI- matched healthy 
women.  
Methods: Participants dietary intake was recorded using pre-coded food diaries.  
Participants’ eating behaviour was assed by using two questionnaires (binge eating 
scale (BES) and three-factor eating questionnaire (TFEQ).   
Results: No statistical significant difference in macro- and micronutrient intake 
between the PCOS and control group was demonstrated. Both groups underreported 
their food intake and reported diets with a high energy percentage from saturated fat 
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and low content of fiber, certain vitamins (e.g. folate, thiamine, riboflavin and vitamin 
D) and iron. No statistical significant difference in antioxidants and micronutrient 
plasma levels between the two groups was found. Women with PCOS had higher 
serum ferritin levels, but the difference was not statistically significant.  
Both BMI and waist circumference correlated negatively with plasma concentrations 
of several antioxidants such as lycopene, xanthophyll, beta-carotene and vitamin C. 
Strong positive correlation between waist circumference, BMI and serum ferritin 
levels were demonstrated in the PCOS group, but not in BMI-matched controls.  
Women with PCOS presented higher BES and TFEQ scores, but the difference was 
not statistically significant.  
Conclusion: When matched for BMI, women with PCOS had similar diets and 
antioxidant blood levels as well as eating behaviour to controls. However, increased 
BMI was associated with emotional eating and binge eating as well as with low levels 
of several antioxidants. The importance of an adequate diet in attention of the 
negative health outcomes women with PCOS are at risk of seems evident and a 
balanced diet within the present recommended levels should be advised. An extra 
attention should be given to those with a BMI not within the normal range.  
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1. Polycystic ovary syndrome: a complex 
endocrine disease 
Polycystic ovary syndrome (PCOS) is a prevalent and frequently encountered 
endocrine disorder that was first described by Stein Leventhal in 1935. It has been 
suggested that this disorder occurs in 5% of women at reproductive age (1).   
Svein Leventhal described PCOS as a syndrome with pathognomonic findings and the 
clinical triad of hirsutism, amenorrhea, and obesity. Since then there has been some 
debate as to whether the syndrome represents a single disorder or multiple associated 
pathologic conditions. PCOS is primarily characterized by hyperandrogenism, insulin 
resistance, and chronic anovulation. Hyperandrogenism and insulin were linked as 
early as 1921, when Achard and Thiers published a classic description of bearded 
women with diabetes (1).   
PCOS is considered, today, a common endocrine condition in premenopausal women 
with reproductive and metabolic consequences, including anovulation, infertility and 
an increased prevalence of diabetes mellitus. Obesity, particularly central obesity, and 
insulin resistance are considered now as strongly implicated in its aetiology (2). The 
syndrome has been also associated with dyslipidemia, hypertension, non-alcoholic 
fatty liver disease, sleep apnea, with increased risk of cardiovascular disease and 
hyperestrogen-related cancers (i.e. endometrial and breast cancer). Therefore, the 
syndrome is considered not only a reproductive problem but a complex endocrine 
disease with important health implications.  
Three main hypotheses have been proposed as implicated in PCOS aetiology (3):   
1. hypothalamic-pituitary axis abnormalities that cause increased ovarian           
androgen production. 
2. an enzymatic defect of ovarian steroidogenesis that favours excess 
androgen   production. 
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3. insulin resistance driving the metabolic and reproductive abnormalities 
in PCOS women. This hypothesis will be discussed in more detail below. 
1.1 Diagnostic criteria for PCOS 
According to the National Institutes of Health, basic diagnostic criteria for PCOS 
include the presence of chronic oligo-anovulation and signs of hyperandrogenism 
such as hirsutism or male-pattern hair loss, with the exclusion of other causes of 
hyperandrogenism.  
An international consensus group revised the diagnostic criteria at a consensus 
conference held in Rotterdam and broadened the definition by also including ovarian 
morphology (3-7). The diagnostic criterion proposed by this international consensus 
requires two of following three criteria: menstrual irregularity, such as oligo- or 
anovulation, biochemical or clinical signs of hyperandrogensim and polycystic 
ovaries on ultrasound. In both definitions, hyperandrogenism has to be documented 
either by biochemical data or clinical signs. Laboratory abnormalities in PCOS can be 
expressed by elevated levels of testosterone, luteinizing hormone (LH), follicle-
stimulating hormone (FSH), and low sex hormone-binding protein (SHBG) 
concentrations. 
Table 1: Diagnostic Criteria for PCOS (1):  
Clinical Features: 
Menstrual irregularity: amenorrhea 
                                     oligomenorrhea 
                                     menorrhagia 
Anovulatory infertility 
Hirsutism and/or acne 
Central obesity 
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Endocrine abnormalities on Laboratory Tests: 
 
Elevated androgen levels (testosterone) 
Elevated LH concentration 
Elevated FSH level 
Insulin resistance with hyperinsulinemia 
Ultrasound examination: 
Multiple subcortical follicular cysts 
Increased ovarian stromal density and/or volume 
                                                                                          
The clinical features of PCOS are heterogeneous and may change throughout the 
lifespan. Hyperandrogenism and menstrual irregularities represent the major 
complaints in young women with the PCOS; oligorrhoea or amenorrhoea and, 
particularly, infertility are the main complaints of adult women with PCOS during the 
reproductive age. The rate of spontaneous abortions is increased as well.  
There are also other causes of menstrual irregularity and hyperandrogenism such as 
androgen-secreting neoplasms, late-onset congenital adrenal hyperplasia, Cushing 
syndrome, hyperprolactinemia, hypo- and hyperthyroidism(1;3;4). The diagnostic 
criteria for PCOS require for all these diseases to be evaluated and excluded through a 
detailed medical history, medical examination and biochemical tests.  
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1.1.1 Medical history and physical examination 
A detailed medical history, focused primarily on symptoms related to pubertal 
development and menstrual regularity, is very important in the diagnosis of PCOS, as 
precocious puberty can be associated with hyperandrogenism (1;8). The 
pathophysiology of PCOS may have a genetic component (1;4;5;9) and performing a 
complete family medical history is relevant.  
Physical examination should focus on establishing the presence of clinical 
components, especially the presents of hirsutism and acne. Gynaecologic examination 
should assess the cysts by palpation of ovaries and ultrasound examination. The 
presence of eight or more follicle less than 10 mm in diameter, at ultrasound, 
classifies the ovary as polycystic.  These modifications are found in 90% of the 
women with PCOS but can also be present in about 25% of women without PCOS 
(10;11). Ultrasonography thus is though not sufficient to diagnosis PCOS but is a very 
important tool to confirm the ovarian findings.  
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2. Background of the current study 
Cardiovascular disease remains the leading cause of death in women, and there are a 
number of modifiable and non-modifiable risk factors for cardiovascular disease. 
According to prospective studies, PCOS patients have a higher prevalence of 
cardiovascular risk factors such as hypertension, type 2 diabetes and dyslipidaemia 
(12). Insulin resistance is implicated in PCOS aetiology and up to 30-70% of women 
affected with PCOS are obese (3), a condition that has been found to increase the 
magnitude of underlying insulin resistance.  
2.1 PCOS and Obesity 
Obesity has existed in the population throughout recorded history, but only in recent 
generations it has increased to an extent that public health experts are calling it an 
epidemic. Since the mid-1980s, the prevalence of obesity has increased steadily and 
markedly in both Westernized and non-Westernized countries, and there are no 
indications that this trends is abating. Overweight and obesity are strongly associated 
with the PCOS (13-15). Although the cause of this association remains unknown, 
obesity is present in at least 30% of cases and, in some populations, the percentage 
may be as high as 75%. Obesity, especially central obesity, has an important impact 
on the severity of all manifestations in PCOS (16). Studies in early adolescence 
support the role of obesity in the expression of PCOS features (14;17-19).  
The increasing prevalence of obesity among adolescent and young women with PCOS 
may partly be due to the increasing worldwide epidemic of obesity. The prevalence of 
PCOS seems to increase and it can be suggested that the main factors responsible for 
this increasing are related to the influence of the environment, including dietary 
habits, behaviour and other still undefined factors (14).  
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2.1.1 Obesity represents a functional hyperandrogenic state. 
There is now consistent evidence that the increase in body weight may favour a more 
severe hyperandrogenism in women with PCOS. Moreover, one of the clinical and 
laboratory features of PCOS is hyperandrogenism. Normally, less than three percent 
of testosterone circulates freely in serum. Most circulating androgens (e.g. 
testosterone) are bound, primarily to SHBG and any condition that decreases the 
levels of SHBG or other binding proteins can lead to a relative excess of circulating 
androgens. The major conditions that are linked with decreased SHBG are PCOS and 
obesity, independently (1).  
2.1.2 Central obesity, insulin and SHBG 
Central obesity in PCOS is associated with more pronounced hyperandrogenism and 
insulin resistance than the peripheral body fat phenotype. Several studies concluded 
that, compared with normal weight women with PCOS, obese women are 
characterized by a worsened hyperandrogenic and metabolic state, irregular menses 
and ovulatory performance and poorer pregnancy rates. Levels of the SHBG tend to 
linearly decrease with increasing body fat. It is well established that, in women, the 
abdominal obesity phenotype is associated with a marked decrease of SHBG levels 
and some increase in total and free testosterone (20-23), which is consistent with a 
state of relative hyperandrogenism. Women with central obesity usually have lower 
SHBG concentrations compared with women with peripheral obesity (24). Increased 
visceral fat development may occur much earlier than general fat excess in the natural 
history of PCOS, leading in turn to the development of insulin resistance and 
associated hyperinsulinaemia and to a hyperandrogenic state (5;15).  However, the 
role of obesity in the development of hyperandrogenism is still being debated.  
2.1.3 Hyperandrogenism, a link between obesity and PCOS 
SHBG levels are regulated by a complex of factors (estrogens, iodothyronines and 
growth hormone (GH) are stimulating factors; androgens and insulin are inhibiting 
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factors). The network of this regulation, with the dominant role of insulin, which 
inhibits SHBG synthesis in the liver, may be responsible for the decrease of SHBG 
concentrations observed in obesity. Obesity, in fact, is associated with 
hyperinsulinaemia that compensates for the presence of insulin resistance. All these 
conditions could explain lowered SHBG concentrations. This is what occurs 
particularly in the presence of the abdominal phenotype of obesity. Women with 
central obesity usually have lower SHBG concentrations compared with age- and 
weight-matched women with peripheral obesity (25). In addition, women with central 
obesity have higher testosterone and dihydrotestosterone production rates which may 
exceed their metabolic clearance rates. Moreover, an increased production rate occurs 
even for androgens not bound to SHBG, such as dehydroepiandrosterone and 
androstenedione. Therefore, the abdominal phenotype of obesity can be defined as a 
condition of relative functional hyperandrogenic state. Abdominal obesity per se may 
play a key role in determining both altered androgen metabolism and insulin 
resistance (5).  
 
Overall, obesity in PCOS significantly changes the reproductive and endocrine 
environment of PCOS. Obesity in combination with PCOS is associated with worse 
androgenic profile, increases the rate of menstrual disturbance and the risk of 
endometrial cancer as well. 
The importance of obesity in the pathogenesis of PCOS is emphasised by the efficacy 
of lifestyle intervention and weight loss, not only on metabolic alterations but also on 
hyperandrogenism, ovulation and fertility (discussed in detail below). This may have 
great relevance in preventive medicine and offer the opportunity to expand our still 
limited knowledge of the genetic and environmental background favouring the 
development of the PCOS.  
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2.2 PCOS, Insulin Resistance and Type 2 Diabetes 
The metabolic profile noted in women with PCOS is similar to the insulin resistance 
syndrome, a clustering within an individual of hyperinsulinemia, mild glucose 
intolerance, dyslipidemia, and hypertension (26;27). PCOS may be considered a 
component of the metabolic syndrome.  On the other hand, the most significant 
metabolic complication of PCOS is insulin resistance, accompanied by compensatory 
hyperinsulinemia, which places women with PCOS at an increased risk for the 
development of hypertension, dyslipidemia, type 2 diabetes mellitus (28-30).   
The insulin resistance syndrome has been identified as both a risk factor for 
developing type 2 diabetes and a major cardiovascular risk factor (31). Furthermore, 
evidence shows that both lean and obese women with PCOS have increased insulin 
resistance and impaired beta-cell function and are at a markedly increased risk of type 
2 diabetes (3;32).  
Cibula et al. showed that despite the identical risk for the development of type 2 
diabetes and cardiovascular disease, the prevalence of type 2 diabetes was 
significantly higher in PCOS women compared with healthy women. These results 
confirmed that women with markedly expressed clinical symptoms of PCOS make up 
a subgroup in the general population, at high risk for the development of diabetes and 
heart disease. Subjects with PCOS appear to have a greater risk for developing type 2 
diabetes, regardless of ethnicity, compared with age- and weight-matched healthy 
controls (33).   
2.3 PCOS and Cardiovascular Disease Risk Factors 
After several decades of research there is general agreement that there is an 
association of increased cardiovascular risk factors with PCOS (32). These risk 
factors are increased by obesity and place obese women with PCOS at potentially 
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higher risk for cardiovascular disease in part because of lipid disturbance that 
accompany PCOS. 
2.3.1 Serum lipid profile in PCOS 
Hypertriglyceridemia and decreased high-density lipoprotein are relatively common in 
women with polycystic ovary syndrome. Elevations in low-density lipoprotein have 
also been noted. Results showed that elevated insulin resistance and plasma 
homocysteine levels, and changes in serum lipid profile, which are possible risk 
factors for cardiovascular disorders, play important roles in the development of 
cardiovascular disease in both obese and non-obese patients with PCOS (34;35). 
Women with obesity and PCOS demonstrated increased insulin resistance when 
compared with controls and it is postulated that insulin resistance is the mediating 
factor in cardiovascular risk (36).   
Obese women with PCOS in their 30s were compared with weight-matched women 
without PCOS. Lipid profiles indicated higher total cholesterol and triglycerides in 
PCOS women (36).  
Another study showed that plasma free fatty acid correlations were markedly 
increased in obese women with PCOS, closely associated with the lower insulin 
sensitivity and lower glucose tolerance in these women. In spite of these profound 
metabolic aberrations, the lipoprotein lipid profile was not significantly more 
abnormal in obese women with PCOS than in their weight-matched controls (37).  
2.3.2 Subclinical signs of cardiovascular disease in PCOS 
Subclinical measures of cardiovascular disease include carotid intima media thickness 
(IMT) and brachial artery flow-mediated vasodilatation and may be predictive of 
cardiovascular mortality. The existing data suggest that PCOS may adversely affect or 
accelerate the development of an adverse cardiovascular risk profile, and even of 
subclinical signs of atherosclerosis. Surrogate markers for cardiovascular disease (i.e. 
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carotid artery intima-media thickness, coronary artery calcification, and C-reactive 
protein) are found to be abnormal in these patients (3). Women with PCOS had 
increased arterial stiffness and decreased flow-mediated vasodilatation (36). This 
study did not demonstrate an increase in carotid IMT, although other studies have 
demonstrated increased IMT in obese women with PCOS (38;39).  
2.4 PCOS and Oxidative stress 
Oxidative stress is an imbalance between tissue oxidants and antioxidants and may be 
a unifying mechanism in the development of major diseases such as cardiovascular 
disease and diabetes type 2. There is considerable evidence that hyperglycaemia, 
hyperinsulinemia and insulin resistance result in greater reactive oxygen species 
(ROS) production that contributes to oxidative stress and that this greater oxygen 
species production may be beyond the capacity of the antioxidant defence 
mechanisms. Antioxidant defences, both intrinsic and of dietary origin are very 
important in neutralizing excessive and inappropriate ROS formation (40-42). High 
intakes of fruit and vegetables or, high circulating levels of their biomarkers 
(carotenoids, vitamin E, C) have been associated with a relative low incidence of 
cardiovascular disease (43).   
2.4.1 Antioxidants of dietary origin 
Several clinical studies have pointed to the protective effect of antioxidant nutrient 
such as beta-carotene, vitamin C, vitamin E, selenium and zinc, for cardiovascular 
disease, type 2 diabetes and cancer (44). Extensive studies have shown an inverse 
association between carotenoids, vitamin E and C intake from the diet and lifestyle 
diseases. Fruit and vegetables are known to be important sources of vitamins (e.g. 
vitamin C, and folate), fiber and, also of a wide variety of phytochemicals (e.g. 
carotenoids). There is a large body of epidemiological evidence that supports the 
hypothesis that vegetables and fruit are protective against type 2 diabetes (45) and 
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cardiovascular disease (46).  Numerous epidemiological studies have also 
demonstrated that individuals with higher dietary consumption of foods rich in 
carotenoids have lower risk of cardiovascular diseases (43).     
A high and varied consumption of fruit and vegetables is desirable because it provides 
a range of nutrients and, additionally, could play an important role in improving the 
dietary patterns by replacing other, less favourable foods in the diet.  
2.4.2 Plasma antioxidants  
Increased oxidative stress and decreased antioxidant capacity has been show to 
contribute to the increased risk of cardiovascular disease in women with PCOS, in 
addition to known risk factors such as insulin resistance, hypertension, central obesity, 
and dyslipidemia (43). Lower antioxidant concentrations among patients with 
metabolic syndrome (47) and diabetes (48) were observed and these findings could be 
explained by a lower intake of antioxidants, increased use of antioxidants, or both.  
Some studies have provided evidence that obesity could contribute to oxidative stress, 
but the exact mechanisms are still not understood. Several studies suggested that 
abdominal adiposity is an independent risk factor for cardiovascular disease (43), 
possible through increased oxidative stress. Thus, there may be a difference in 
oxidative stress between individuals with or without increased abdominal obesity.  
There is, however, unclear whether blood concentrations of antioxidants are lower in 
obese people and there are several studies that investigated the determinants of serum 
levels of antioxidants in both men and women. It has been suggested that different 
obesity measures such as BMI, waist circumference and waist to hip ratio are 
important predictors of plasma concentrations of different antioxidants, but the results 
have been inconsistent (49). Moreover, serum levels of carotenoids and vitamin C 
have been demonstrated to be influenced by other factors, especially smoking. These 
aspects are shortly presented below.  
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Predictors of carotenoids and retinol levels 
Serum levels of carotenoids and retinol have been shown to be influenced by sex, 
smoking, alcohol use, BMI and oral contraceptive use (50). The population-based 
data from NHANES 3 suggested that carotenoid concentrations are associated with 
insulin resistance, glucose tolerance status (47), conditions women with PCOS are 
shown to be at risk of.  
It was shown that women with abdominal obesity as determined by high waist 
circumference and waist hip ratio are significantly and independently associated with 
oxidative stress as determined by decreased serum levels of several carotenoids (i.e. 
alpha-, beta-carotene, lycopene, lutein) (43). In an article published recently it was 
shown that BMI is inversely associated with plasma concentration of carotenoids 
(51).   
Most of the studies pointed that beta-carotene concentrations are associated with 
obesity. Accordingly, BMI has been reported to be independently related to beta 
carotene concentrations in obese subjects of both gender (44) and several reports 
among females consistently showed that serum beta-carotene was negatively 
associated with BMI and with other measures of obesity (52-54). There are, however, 
reports that showed that plasma alpha- and beta-carotene were not correlated with any 
anthropometric variable (55) and no association of BMI with beta-cryptoxanthin and 
lutein + zeaxanthin was found (56;57). 
Predictors of Vitamin C levels 
Reports consistently showed that plasma vitamin C levels are negatively correlated 
with BMI and other measures of obesity in women, even after correcting for age, 
body mass and vitamin C supplement use (44). Another study conducted among 
participants from both gender showed that higher waist to hip ratio was associated 
with lower vitamin C levels (49). On the other hand, there are published reports that 
found no relation of obesity, assessed by BMI, with plasma vitamin C (51;58).  
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Predictors of alpha- and gamma-tocopherol levels 
Gamma tocopherol was shown to be positively associated with BMI in several studies 
(54;59). 
On the other hand, negative association between serum alpha-tocopherol and both 
general and central obesity (60;61) were observed, whereas no associations were 
found in two other studies (55;62).   
Smoking, plasma carotenoid and vitamin C concentrations 
Several studies reported that serum carotenoid and vitamin C levels are affected by 
various factors, such as smoking and drinking habits, physical exercise and age. 
Especially smoking is known to generate reactive oxygen species in vivo and it has 
been reported that serum levels of carotenoids and vitamin C are lower in smokers 
compared to non-smokers (63). Current smokers of both sexes were shown to have 
significantly lower concentrations of beta-carotene and vitamin C (44). 
2.5 PCOS and Lifestyle 
Research consistently demonstrates that lifestyle interventions such as diet and 
exercise should be the primary goal of treatment in PCOS patients, particularly if they 
are overweight. Among several other mechanisms, hyperinsulinaemia plays a 
fundamental role in PCOS, which has been demonstrated both in vitro and in vivo 
(28;64;65).   Menstrual cycles and fertility rate are negatively affected by the presence 
of insulin resistance, hyperinsulinaemia and obesity. There are several trials, all with 
relatively small sample sizes, that consistently show improvement in reproductive 
parameters with weight reduction in PCOS.  
2.5.1 Weight loss 
There has been much discussion in recent years on the role of specific dietary 
components on weight reduction in PCOS. Currently, a diet low in saturated fats with 
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an increase in dietary fiber with predominantly low glycemic-index carbohydrates is 
recommended.  
Glycemic index is a classification of carbohydrates based on their effects on blood 
glucose response over 2 hours. Low glycemic index foods include bran cereals, mixed 
grain breads, lentils, and soy. High glycemic index foods include white rice and 
bread, potatoes, and sweets containing simple sugars. 
Several studies have looked at a comparison of low carbohydrate to standard dietary 
intervention regimens in both amount of weight lost as well as specific metabolic and 
endocrine features of PCOS. Douglas CC et al. showed that a eucaloric low CHO 
diet, which was relatively low in carbohydrate (43%) and cholesterol, high in fiber, 
and comprised of 45% fat (18% monounsaturated fat and <8% saturated fat), 
improved the metabolic profile of women with PCOS within 16 days (28).   
Body weight loss and dietary changes is associated with beneficial effects on clinical, 
endocrinological and metabolic features of obese women presenting both PCOS and 
hyperinsulinemia (28;66). Dietary weight loss is usually followed by reduced 
hyperandrogenism and hyperinsulinemia and improved clinical status (menstrual 
regularity, less hirsutism, and increased fertility rate) in many obese women with 
PCOS (67-70). The central role of improved insulin concentrations and insulin-
resistant state is emphasized by the fact that similar effects can be achieved by both 
short- and long-term administration of metformin (an insulin-lowering drug which 
ameliorates peripheral insulin action in non-diabetic insulin resistant states) (14).  
Studies of obese women with menstrual abnormalities have demonstrated that cycles 
can potentially normalize and fertility been re-established following weight loss (1). 
The most frequent measure of restoration of reproductive function is menstrual 
cycling or return of ovulation. It has been shown that even short term treatment of 
obese PCOS women lead to fall in serum insulin and improvement in hormone levels 
and restore regular ovulatory menstrual cycles and fertility (69;71). Lifestyle 
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modification with modest weight loss goals of 5-10% appear to be equally effective in 
restoring fertility and may be more compatible with long-term success (14).  
Long-term treatment with metformin added to hypocaloric diet induced, in PCOS 
women with abdominal obesity, a greater reduction of body weight and abdominal fat, 
more decrease of serum insulin and testosterone compared with placebo. These 
changes were associated with a significant improvement of hirsutism and menses 
abnormalities (72).  
The Journal of the Norwegian Medical Association and Norwegian Society of 
Gynaecology and Obstetrics highlighted that lifestyle factors, especially diet and 
weight loss, are important factors in the development and treatment of polycystic 
ovary syndrome. Lifestyle modification with modest weight loss goals of 5-10 % 
appear to be equally effective in restoring fertility in 20% of cases (73). 
2.5.2 Diet 
Diet, Heart Diseases and Diabetes 
Epidemiological and clinical research have identified physical activity, excess calorie 
consumption and excess weight as common risk factors for both cardiovascular 
disease and diabetes type 2. A substantial body of research have been pointed that a 
diet with about 30 E% fat, less than 10 E% saturated fat, and rich in fruit, vegetables 
and wholegrain cereal in combination with physical activity can reduce the risk of 
diabetes and heart disease (74;75) in the general population, conditions which PCOS 
women are at high risk to develop.   
Experimental evidence has indicated that typical western diet, which is high in fat and 
refined carbohydrate and low in fiber, induces insulin resistance and precedes obesity. 
Evidence, from epidemiological studies, suggests an association between 
consumption of fruits, vegetables, and high fiber complex carbohydrates and a 
reduced risk of cardiovascular disease (76;77). It is not known for certain which 
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active dietary constituents or combination of constituents and what are the 
mechanisms that contribute to these protective effects (78).   
The components of diet currently recommended as "healthy" are likely also protective 
against metabolic syndrome, including low saturated and trans fat, balanced 
carbohydrate intake rich in dietary fiber, as well as high fruit and vegetable intake and 
the inclusion of low-fat dairy foods. Extensive studies have shown an inverse 
association between cardiovascular disease and vitamin E and carotenoids from the 
diet and based on these data high intake of fruits and vegetables has been included in 
guidelines against cardiovascular disease (79). Replacing refined grain products with 
minimally processed plant-based foods such as fruits, vegetables, whole grains and 
reducing the intakes of high glycaemic index beverages may offer a simple strategy in 
for reducing the incidence of heart diseases (80). The health benefits of dietary fiber 
in reducing the risk of chronic diseases have been well-established. Several lines of 
evidence also suggest that dietary fiber may play a key role in the regulation of 
circulating insulin levels (81;82). Fiber reduces insulin secretion by slowing the rate 
of nutrient absorption following a meal and several studies showed that insulin 
sensitivity increases and body weight decreases in people on high fiber diets (83;84).    
Diet and PCOS 
Compared with matched control women, women with PCOS exhibited a dietary 
pattern that was marked by consumption of a greater amount of specific foods with a 
high glycemic index; however, diet composition was not associated with the greater 
fasting insulin concentration or with lower glucose-to-insulin ratio that was observed 
in the PCOS group (64).  
In an article published recently, Moran LJ et al. emphasized that a moderate fat intake 
or carbohydrate restriction is equally effective in improving reproductive and 
metabolic variables in women with PCOS (85). Results from a clinical trial also 
showed that increased dietary polyunsaturated fatty acids (PUFA) intake can exert 
significant metabolic and endocrine effects in women with PCOS (86).  
 31 
Moreover, Farshchi H et al. made recommendations on macronutrient intake that 
could improve endocrine features, reproductive function and cardio metabolic risk 
profile. They pointed that a restriction of fat intake to 30 E% or below 30 E% of total 
energy intake, with a low proportion of saturated fat, distributed between several 
meals per day could be beneficial even when marked weight loss is not achieved. 
They also emphasized that both diet and exercise need to be tailored to the women’s 
need and preferences (87).  
Evidence suggest also that diet not only ameliorate many of the features of the 
metabolic syndrome, present in women with PCOS, but also could reduce risk for 
atherothrombosis and type 2 diabetes mellitus in these patients (88). Individualized 
pharmacological support aimed at favouring weight loss and maintenance and 
improving insulin resistance may play a complementary role to lifestyle intervention 
in PCOS women (89). 
2.6 PCOS and Micronutrient status 
2.6.1 Iron 
There is now increasing evidence that moderately elevated body iron stores, below 
levels commonly found in genetic hemochromatosis, may be associated with adverse 
health outcomes. Elevated serum ferritin levels independently predicted type 2 
diabetes and several cross-sectional studies showed that elevated serum ferritin is 
associated with hypertension, dyslipidemi and metabolic syndrome (90). There is 
evidence that iron stores, measured by serum ferritin concentration, are related to the 
degree of insulin resistance in women and with increased prevalence of metabolic 
syndrome (90). However, not much is known about the association between iron 
stores and polycystic ovary syndrome.  
Indeed, increased serum ferritin levels, indicating increased body iron stores, have 
been found in overweight and obese women with PCOS (91).   
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2.6.2  B vitamins and folate 
There are published several studies that investigated vitamin B12 and folate levels in 
women treated with metformin. In nonpregnant women both serum folate and vitamin 
B12 levels decreased with metformin treatment but serum homocysteine levels did 
not increase (92). In contrast, a study that compared two medical treatments in PCOS 
patients (metformin and rosiglitazone) showed that treatment with either of these 
medicines may lead to increases in homocysteine levels (93). Moreover, women with 
insulin resistance have higher homocysteine levels than those who are not insulin 
resistant (94).   
Results from a study in PCOS women on metformin treatment suggest that B-group 
vitamins and folic acid administration counteract the homocysteine - increasing effect 
seen with metformin therapy (95). In patients with type 2 diabetes, metformin reduces 
levels of folate and vitamin B12 and increases homocysteine concentrations. 
Conversely, rosiglitazone decreases homocysteine levels in this time period. The 
clinical significance of these findings remains to be investigated (96). 
 
There is now consistent evidence that there is a strong association between diet, 
vitamin and antioxidant intake, nutritional status and prevention and treatment of 
several lifestyle diseases. Furthermore, oxidative stress may play a central role in the 
pathophysiology of diabetes and cardiovascular disease. Still, little is known about 
macronutrient and micronutrient intake and vitamin and mineral status among women 
with PCOS who are at high risk for developing these conditions.  
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2.7 PCOS and Eating disorders 
Body dissatisfaction is widely accepted to play an important causal role in eating 
disorders and a link between PCOS and eating disorders, specifically bulimia, has 
been suggested by several studies (97).  
McCluskey S et al. reported that one third of women with PCOS at an outpatient 
endocrine clinic scored in the abnormal range on a standardized test of eating 
behaviour with 6% in the bulimic range (98). On the other hand several studies found 
that bulimia may lead to polycystic ovaries (99).  
Compared with healthy women, PCOS patients have reduced secretion of 
cholecystokinin (a satiety peptide) causing abnormal appetite regulation and possibly 
leading to the tendency to binge (100). Binging and starving cycles may create 
changes in insulin sensitivity and androgen levels, in turn affecting ovarian 
morphology (99;101).  
 
In order to assess eating attitudes two questionnaires have been widely used and 
validated: the binge eating scale, developed by Gormally J et al. (102) and three-
factor eating questionnaire, developed by Stunkard and Messik (103).   
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3. Aims and Hypothesis 
The main aim of this master thesis was to examine dietary intake, nutritional status in 
regard to selected vitamins and minerals and eating behaviour in PCOS patients.  
3.1 Aims 
 
- To examine macro-, micronutrient, and fiber intake in a group of women with 
PCOS    group and a control group and compare these intakes in the two 
groups. 
- To measure micronutrient status in both groups using biochemical analysis 
and to identify potential deficiencies, and compare the results from the two 
groups.  
- To examine whether there is an association between antioxidant status and 
obesity measures in both groups. 
- To examine eating behaviour in both groups using BES and TFEQ and to 
examine whether there is an association between BMI and the scores of these 
questionnaires.  
3.2 Hypothesis 
H01: Dietary consumption of total energy, macronutrients, micronutrients and fiber is    
similar in women with PCOS and controls.  
H02: Women with PCOS do not have lower blood vitamin and mineral concentrations 
compared with healthy age- and BMI matched controls.  
 35 
H03: There is not an association between obesity measures and plasma levels of 
antioxidants  
H04: BES and TFEQ scores are similar in women with PCOS and controls. There is 
not an positive association between BMI and these scores. 
 
HA1: Consumption of total energy, macronutrients, micronutrients, and fiber is not 
similar between the groups.  
HA2: Women with PCOS have lower vitamin and mineral levels compared with 
healthy age matched controls.  
HA3: There is an association between obesity measures and plasma levels of 
antioxidants 
HA4: BES and TFEQ scores are not similar in women with PCOS and controls. There 
is a positive association between BMI and these scores. 
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4. Subjects and Methods 
This pilot study was conducted at Stavanger University Hospital between the months 
of September and December 2007. In summary, demographic, anthropometric, 
dietary, eating behaviour and laboratory data from women with polycystic ovary 
syndrome were compared to age- and body mass index matched controls. We used 
standardised questionnaires and a detailed seven-day food diary. Weight, height, waist 
to hip ratio, relevant medical history and pharmaceutical therapy were recorded in a 
personal interview.  
4.1 Patient and Control Selection 
Twenty five women with PCOS were recruited from the Stavanger University 
Hospital, Department of Medicine, Section of Endocrinology, Outpatient Clinic and 
other units at the Stavanger University Hospital. At the beginning of the study the 
student searched on in the internet (World Health Organization, WHO) for the ICD-
10 code for polycystic ovary syndrome in the International Statistical Classification of 
Diseases and Related Health Problems 10th Revision (ICD-10). The List of ICD-10 
codes is a coding of diseases, symptoms, signs, social circumstances and external 
causes of injury or diseases, as classified by WHO. The code for PCOS is E28.2, from 
ICD-10 chapter IV, block E00-E90, title Endocrine, nutritional and metabolic 
diseases, subtitle Disorders of other endocrine glands (E20-E25), Ovarian dysfunction 
(E28) (104).  
There were 74 women that had been diagnosed with PCOS, as the first or second 
diagnosis, at Stavanger University Hospital. Potential participants with one or more of 
the following conditions were excluded:  
• A history of type 2 diabetes mellitus. 
• Pregnancy. 
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• Any known condition with impact on the nutritional status such as cystic 
fibrosis, malabsorption, celiac disease, inflammatory bowel disease (Crohns 
disease and ulcerative colitis), known eating disorders.  
• Ongoing diet program such as weight loss dietary program. 
 
All the questions regarding diagnoses and other medical conditions of potential 
subjects were discussed with the internal and external supervisors of the project, 
Professor Serena Tonstad and Dr. Med. Svein Skeie.   
Diagnostic criteria for inclusion in the study required two of the three following 
criteria: oligo- or anovulation, biochemical or clinical signs of hyperandrogenism, and 
polycystic ovaries on ultrasound. The participants with other diagnosed 
endocrinological disorders, e.g. hypothyroidism, could enter the study as long they 
were treated and the condition was stable.  
Based on diagnostic criteria, inclusion and exclusion criteria, 56 patients were invited 
to take part in the project. Every patient received one invitation letter with an attached 
informed consent form (see appendix B and C). Women who were interested in 
participating in the study returned the informed consent to the Stavanger University 
Hospital, addressed to the external supervisor. Eleven potential participants responded 
positively to the invitation during the first three weeks after they received the 
invitation. The student telephoned all the patients who had not answered the invitation 
within three weeks after they received the letters in order to invite them to participate 
in the project, explain the conduct of the study and to answer any questions. There 
were 13 patients that responded positive due to conversation on the telephone. 
Potential participants were invited to call the project staff at any time with questions.  
 
Patients were classified into three groups according to BMI: six had normal weight 
(BMI 18.5-24.9), overweight (25-29.9) and obese (30 or above). The distribution was 
as follows: six normal weight, eight overweight and 11 obese patients. 
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Control subjects were than selected to give the same number of controls in each BMI 
group. The control group of twenty five healthy, age- and BMI matched control 
women who were recruited from the hospital staff, excepting healthcare workers; 
controls were also recruited through Stavanger Lærings og Mestringssenteret and 
from staff working at two driving schools. Potential controls were invited to 
participate in the study and informed about the study by e-mail or phone. Women who 
were interesting in participating in the project could answer either the external 
supervisor or the student.  
All the participants were promised individual nutritional counselling after all the data 
are gathered and investigated.   
4.2 Methods of Data Collection 
The student conducted a one hour long interview with every participant and relevant 
medical history, pharmaceutical therapy, weight, height and waist/hip ratio for every 
participant were recorded.  
4.2.1 Anthropometrical measures 
The student measured each participant’s weight, height, waist and hip circumferences 
once before the participant recorded her dietary intake. 
Weight was measured with a digital scale (+/-0.1 kg) with subjects dressed in light 
clothes (i.e. T-shirt/sweater, pants, socks) and without their shoes on. Height was 
measured to the nearest centimetre (cm). BMI was calculated as body weight (kg) 
divided by the square of height (kg/m2) and waist to hip ratio (WHR) was calculated 
as waist circumference (cm) divided by hip circumference (cm). Waist circumference 
was measured as the minimum value between the iliac crest and the lateral costal 
margin, whereas hip circumference was determined as the maximum value over the 
buttocks, using a 1-cm-wide metal measuring tape. 
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4.2.2 Dietary Assessment 
The dietary monitoring period was seven consecutive days, including two weekend 
days; the recording of the diet could start any day during the week, any week, except 
two weeks before Christmas and two weeks after New Year.  
Pre–coded food diary 
The traditional food record method may provide a detailed dietary assessment, but 
requires much work by the participants. To simplify the work for both the participants 
and the project staff, we used a scannable pre-coded food diary (PFD) (see appendix 
D), that uses household measures and photographs for portion size estimation (105) .   
The PFD lists 277 drinks, food items and dishes that are grouped together according 
to the typical Norwegian meal pattern (105). The PFD includes 28 drinks, 24 dishes 
and 255 food items grouped into following sections: beverages, bread, spread on 
bread, yoghurt, breakfast cereals, milk for breakfast cereals, meat dishes, fish dishes, 
other dishes, mixed salads, potatoes/rice/pasta, vegetables, sauces, dessert, cakes, fruit 
and berries, snacks, sweets and chocolate, supplements. The design of the PFD lists 
food, drinks and dishes on the left side of the page and time span across the top. One 
day is divided in five time spans: four time spans covered 4 hours (e.g. 06.00–10.00, 
10.00–14.00, 14.00-18.00 and 18.00-22.00) and one time span covered 8 hours 
(22.00–06.00) (106).  The amount of food is recorded in different household units, 
depending on the food item (e.g. beverages are recorded in glasses, sauces in 
tablespoons, pizza in slices) and as portion sizes estimated from a portion size booklet 
(see appendix E). The participants were asked to fill inn what they had eaten, how 
many units of that drink/food item they have eaten. The student explained that is also 
important to fill inn the information in the actual time span in order to assess the meal 
pattern. Furthermore, each food group is supplemented with open spaces for drinks, 
food items and dishes not in the PFD list. If the participants had eaten a food item that 
is not in the PFD list, she had to write in the open spaces the name for the drink/food 
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item she had eaten, amount (e.g. what portion size and how many portion sizes), and 
time for the actual meal.  
The participants were asked to record food intake during seven consecutive days and 
they received one pre-coded food diary for each day. They also had to record any 
dietary supplements they used. 
 Along with the food diary each participant was handed a photographic booklet that 
includes 15 color photograph series (107). Every page in the photographic booklet 
includes four different portion sizes. The portion sizes range from small (A) to large 
(D) portion sizes. 
The student carefully instructed every participant how to fill out the food diary. First 
she explained how the PFD is designed and than she gave examples on how the PFD 
had to be filled inn. Furthermore, the student went through one specific example and 
every participant received that paper example. Written instructions on how to fill out 
the food diary were handed to every participant at the end of the meeting. The student 
emphasized that the participants should not make any alterations to their normal diets 
during the recording period. The participants could also call the master student at any 
time with questions. 
To ensure that all participants were familiar with the inclusion criteria, all participants 
had to read the informational letter at the beginning of the meeting and sign an 
informed consent stating that they are familiar with the conduct of the study, and 
volunteer to participate.   
Nutrition Calculation database 
The completed food diaries were computed - scanned and manually checked for 
errors, using the Teleform programme 6.0. Daily food intake, energy and nutrients 
content of the participant’s reported food intake were calculated by using a food 
database and software program developed at the Institute of Nutrition Research, 
University of Oslo, Norway (KBS, 2004). The same person conducted the scanning 
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and verifying. Moreover, a supplementary manually check of the food diaries was 
conducted in SPSS. The database is based on the Food table from 1995 (108). Dietary 
supplements are included in the calculations (cod liver oil, multivitamin – mineral 
supplements, vitamin B-, C, D-, E- supplements, iron, calcium and fluoride).  
4.2.3 Eating behavior assessment 
Binge Eating Score 
In order to assess participants’ eating pattern we used the binge eating scale (BES) 
(see appendix F) that describes both behavioural manifestations (e.g., eating large 
amounts of food) and feeling/cognitions surrounding a binge episode (e.g., guilt, fear 
of being unable to stop eating) (102).   
 Binge eating is a key feature of the binge eating disorders bulimia nervosa and binge-
eating disorder. Binge eating score is an 16-item scale that assesses binge eating 
severity and includes items that describes feeling (e.g. guilt, preoccupation with 
eating restriction) and behavioural manifestations (e.g. eating in secret) (109). Binge 
Eating Scale is a self-reported instrument that measures the severity of binge eating 
and consists of 16 items. For research purpose, investigators have classified subjects 
based on total score into three groups: nonbingers, moderate bingers, or severe 
bingers or set a cut-off point of 27 or higher to identify only the severe binge eaters.  
Three Factor Eating Questionnaire 
The three-factor eating questionnaire TFEQ-R21(see appendix G) used in this master 
project is a revised TFEQ instrument and aggregates three separate scale scores: 
eating behaviour, cognitive restraint and emotional eating scale. The Uncontrolled 
eating scale assesses the tendency to lose control over eating when feeling hungry or 
when exposed to external stimuli. The Cognitive restraint scale assesses the tendency 
to control food intake in order to influence body weight and body shape. The 
Emotional eating scale measures the propensity to overeat in relation to negative 
mood states, e.g., when feeling lonely, anxious, or depressed (110). The student 
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carefully instructed every participant how to fill out the questionnaires which were 
completed by the participants at home.  
4.2.4 Biochemical Measurements 
Requisitions for blood tests were given to all 49 participants about two months after 
the beginning of the study. All the blood samples were taken at Stavanger 
Helseforskning by two trained venipuncturists at the Clinical Chemistry Laboratory.  
Serum levels of nutritional biomarkers of interest, including serum levels of iron, 
vitamin B12. folate, total carotenoids and tocopherols were obtained.  
Table 2 Biochemical measurements 
Nutrient Blood tests 
Iron Haemoglobin, hematocrit, s-iron, ferritin, 
transferrin  
Vitamin B12 Cobalamin 
Folate Folate 
Antioxidant vitamins Retinol, alpha-, gamma -tocopherol, 
vitamin C 
Carotenoids Beta-carotene, lycopene, xanthophyll 
 
Blood values for cholesterol, triglycerides and fasting blood glucose were also 
measured. 
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Blood collection 
Early morning venous blood samples were drawn for biochemical screening tests, 
following a 12-hour overnight fast. All the patients that were on Metfomin treatment 
were asked to stop taking the medication 24 hours before the blood samples were 
taken.  
A biobank was established and all the blood samples were identified with a 
participant number. The samples were either analyzed at the Stavanger University 
Hospital or sent to The Slovak Medical University Nutrition Laboratory, Bratislava, 
Slovakia, for analyses.  
All the blood samples shall be destroyed either when the analyses are completed or at 
the completion of the project. 
The blood was collected first in two serum aliquot tubes, 5 ml blood in each tube, and 
centrifuged. Blood was then collected in two tubes containing 
ethylenediaminotetraacetic acid as anticoagulant, 3 ml blood in each tube. Those four 
aliquots were transferred immediately to the Biochemical Laboratory of the Stavanger 
University Hospital and used for blood analysis of haemoglobin, haematocrit, 
glucose, glycated haemoglobin (HbA1c), triglycerides, total cholesterol, serum-iron, 
ferritin, transferrin, vitamin B12, folate. Analyses were performed on the same day of 
collection.  
Biochemical screening tests 
Serum glucose concentrations were measured using heksokinase method based on the 
work of Schmidt, Peterson and Young, on Roche automated clinical chemistry 
analyzers (111). The glycated haemoglobin determination was based on the 
turbidimetric inhibition immunoassay (TINIA) for hemolyzed whole blood (112). 
HbA1c (%) values were obtained on a Cobas Integra 800 analyzer using Cobas 
Integra Hemolyzing Reagent Gen.2.  
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The quantitative determination of serum iron levels was based on the FerroZine 
method without deproteinizaion and serum ferritin was measured by using the 
“ECLIA” method (electrochemiluminescence immunoassay), on Elecsys 
immunoassay analyzer (113). For the determination of transferrin, the Roche 
transferring assay, based on the immunological agglutination principle, was used 
(114). Triglycerides and Cholesterol levels were measured by an enzymatic 
colorimetric test; the colour intensity of the end product is directly proportional to the 
triglycerides and cholesterol concentrations, that were determined photometrically 
(115).  
Vitamin B12 and Folate serum levels were measured with the Elecsys vitamin B12, 
respectively Elecsys Folate assay. The assay employs a competitive test principle 
using natural intrinsic factor specific for vitamin B12 for the determination of vitamin 
B12 levels, respectively, a natural folate binding protein specific for folate for the 
determination of folate levels (116). 
 
Serum samples for determination of antioxidant vitamins and carotenoids serum 
levels were collected. About 10 ml blood was collected in a Vacutainer (Beckton 
Dickinson) containing heparin as anticoagulant. As soon as possible, the samples 
were centrifuged at 2000 x g for 15 minutes at 4ºC.  The plasma was removed by 
pipette, and aliquots distributed (0.5-1 ml) in micro centrifuge tubes. Samples for 
vitamin C were acidified at this stage, so two tubes were labeled separately and an 
equal volume of 10% (v/v) metaphosphoric acid was added to each of them. The 
tubes was kept on ice while all this was done, and then as soon as all the tubes were 
prepared, they were dropped into a flask containing liquid nitrogen to ’snap freeze’ 
them. The samples were then stored at - 76ºC. 
Serum samples were sent in dry ice to The Slovak Medical University Nutrition 
Laboratory, Bratislava, for analyses. A,C,E vitamin and alpha-, beta-carotene, 
lycopene, lutein, and tocopherols serum concentrations were measured. Ascorbic acid 
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concentrations were measured using high performance liquid chromatography 
(HPLC) by the method of Ross MA (117). Vitamins A and E as well as carotenes and 
lycopene in plasma were measured by reverse-phase HPLC using the method of Hess 
et al. (118).   
4.3 Data Analysis 
All analyses were conducted using The Statistical Package of Social Science (SPSS, 
Inc., Chicago, IL, USA) version 13.0. The level of statistical significance was set at 
the 0.05-level, thus any p-value at this level or lower was considered a significant 
result. 
4.3.1 Descriptive statistics 
Differences between means in groups were compared with T-test. The non-parametric 
alternative Mann Whitney was used to compare groups when data in the groups were 
not normally distributed.  
Comparative statistics 
Macronutrient and micronutrient intake  
Differences in macronutrient and micronutrient intake between the PCOS group and 
their age- and BMI-matched controls were examined. Groups were tested to see if 
they were coming from a normally distributed sample. The paired sample T-test was 
used when the dietary variables met this assumption of normality; otherwise the non-
parametric alternative Wilcoxon Signed Rank test was conducted.  
Serum levels of vitamins and minerals 
Differences between serum levels of measured vitamins and minerals between the 
groups were examined by using the paired sample T-test if the data was normally 
distributed; otherwise the non-parametric test Wilcoxon Signed Rank test was 
conducted.  
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4.3.2 Analyses of correlations  
The correlation is defined as the influence one independent variable (e.g. waist 
circumference) has on one dependent variable (e.g. plasma antioxidant concentration). 
Adjusted correlation is the effect one independent variable has on serum antioxidant 
concentration after adjustment for the other possible cofounding variables, such as 
age and smoking.  
Pearson’s correlation analysis was conducted to look at patterns between body mass 
index, waist circumference, waist to hip ratio and serum levels of antioxidants and 
serum ferritin. This was investigated in our population sample (both PCOS patients 
and controls) and than, in the patient and control group, separately. To check if the 
assumption of normal distribution and linearity were violated, we looked at the shape 
of the scatter plots and the descriptive statistics. Spearman’s correlation analysis was 
used when the assumption of Pearson’s were violated. Any p-value at the 0.01-level 
or lower was considered a significant result. 
4.3.3 Regression analyses 
Univariate analyses  
Univariate analyses were conducted prior to the multivariate analyses. Serum 
antioxidant level was the independent continuous variable. The different independent 
variables were age and measures of obesity, such as body mass index, waist 
circumference and waist to hip ratio.  
Linear multiple regression 
Three different models were created in order to investigate the effect of different 
obesity measures on different antioxidant levels in the two groups.  
Serum antioxidant level was the dependent variables like in the univariate analyses. 
Independent variables were included in the models based on knowledge from former 
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research on factors that influence serum antioxidant levels, independently of their 
level of significance in this study.   
In the multiple regressions analysis when age, smoking and each of the obesity 
measures were included separately, we tested the effect of body mass index, waist 
circumference and waist to hip ratio on variation of plasma antioxidants 
concentrations.  
The assumption of normality and linearity was checked by looking at the descriptive 
statistics and scatter plots. 
4.4 Ethics 
The study was evaluated and approved by the Regional Committee for Medical 
Research Ethics, Western Norway (see appendix A). To ensure that everyone is 
familiar with the inclusion criteria, all participants had to read and sign an informed 
consent stating that they are familiar with the conduct of the study, and volunteer to 
participate.  The identity of all participants was protected; none of them can be 
identified from the report that was used for the master thesis.   
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5. Results 
5.1 Subject characteristics 
Initially there were a total of 27 potential participants with PCOS and the initial 
control sample consisted of 25 women. Two recruited patients decided not to 
participate in the study due to personal reasons and one control was lost because she 
started a special diet before she could start to complete the food diary. This left 49 
subjects, 25 patients, ages between 20 and 42 years old and 24 BMI matched controls, 
ages between 21 and 44 years old. All the participants were, by chance, of Norwegian 
ethnicity.  
Two women in the PCOS group and three women in the control group had 
hypothyroidism but all of them were adequately treated and had normal tyroid 
stimulating hormone (TSH) levels. One patient was diagnosed with celiac disease by 
the time we took the blood samples but this was after she completed the food diary, so 
she had a normal diet. This patient was excluded when we investigated and compared 
micronutrient and antioxidant status from the two groups.  
Twelve participants from the patient group and 15 from the control group reported 
that they took dietary supplements such as multivitamin, B12 vitamin and folate 
supplement, during the registration period. Three participants, two from the PCOS, 
and one from the control group, were taking vitamin B12 injections. One patient and 
two controls were taking folic acid supplement, 0.4 mg/day.  
Nine subjects reported smoking, three from the patient group (12%) and six from the 
control group (25%). The patients and controls were well matched in regard to BMI, 
as shown in table 3. 
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Table 3 Participants categorized according to BMI  
 
                                                                                                                         Group 
                                                                        All                         PCOS group            Control group 
      BMI                                                          N=49                          N=25                        N=24                                     
18.5-24.9 kg/m2                                                               N=12 (24%)             N=6 (24%)                 N=6 (25%) 
25-29.9    kg/m2                                                               N=16 (33%)             N=8 (32%)                 N=8 (33%) 
 > 30        kg/m2                                                               N=21 (43%)             N=11(44%)                N=10 (42%) 
 
Table 4 describes the age and anthropometric characteristics of the subjects 
participating in the study. The patient and control groups were in the same age group 
as well. Data are presented as mean and standard deviation (SD). 
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Table 4 Age and anthropometric characteristics of the participating women 
                                                                                                                     
                                                                                                                     Group 
                                                                        All                         PCOS group        Control group 
Continuous characteristics                         N=49                          N=25                      N=24                             p-value 
Age (years)                                                       33 (7)                               31 (7)                      35 (7)                  0.05 
Weight (kg)                                                     88.6 (24.9)               89.9 (25.6)               87.8  (25)                         0.7 
Height  (cm)                                                     169 (6)                    169 (6)                     169 (6)               0.8 
Waist    (cm)                                                    95 (20)                     98 (21)                    92 (18)                              0.3         
Hip       (cm)                                                    102 ( 17)                1 04 (18)                   101 (18)                             0.6        
Waist to hip ratio                                           0.91 (0.06)              0.93 (0.06)                  0.90(0.06)                        0.07 
 
5.2 Nutrient intake  
5.2.1 Under-reporters 
Energy intake (EI) divided by basal metabolic rate (BMR) gives an estimate whether 
or not subjects are having an EI that is consistent with life over time. Under-reporters 
are subjects with values EI:BMR<1.35, whereas <1.14 is not consistent with life 
(119).  
Table 5 shows the proportion of the participants that were categorised as under - 
reporters.  
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Table 5 Proportion of subjects categorised as under-reporters 
         PCOS group 
N=25 
Control group 
N=24 
 %                                          N %                                          N 
EI:BMR < 1.35 100                                      25 80                                        19 
EI:BMR < 1.14 64                                         16 58                                        14 
 
5.2.2 Macronutrient intake among patients and controls 
Table 6 shows values for energy and energy providing nutrients intake among patients 
and controls. There were no statistical significant differences when comparing the 
self-reported energy and macronutrient intake between the patient group and control 
group. Both groups reported energy provided by fat and saturated fat that was over the 
recommended limits and the dietary fibre intake was under the recommended limits 
(120).  
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Table 6 Macronutrient intake in PCOS and control group 
 
 
 
   PCOS  group (N=25) 
 
           Control group (N=24) 
 Mean      SD         Median     Q1       Q2 Mean    SD    Median     Q1       Q2   P-
value 
Energy (Kj) 
Protein (E%) 
Fat (E%) 
Saturated fat (E%) 
Monounsaturated fat  
(E%) 
Polyunsaturated fat (E%) 
Carbohydrate* (E%) 
Added sugar ** (E%) 
Fiber (g) 
Fiber (g/MJ) 
8259         1720       7935        7519    9216 
17              3             16            15        18 
36              6             35            32        40        
16              3             15            13        17  
12              2             12            10        13 
 
7                2              6               6         8  
45              5            44             42        48 
7                4             6               4         10 
18              6            18            14         23 
0.02         0.008      0.02          0.01     0.02 
8694        1759   8890        7296    9567 
16              3         16            15        18 
37              6         37            32        40 
15              2         15            13        16 
12              2         12            10        13 
 
7                2          7              5          8 
45               6       45             41        50        
10               7         9             5          13                    
19               7        16           13         23 
0.02       0.006      0.019      0.01       0.02 
0.4 
0.5 
0.6 
0.7 
0.7 
 
0.5 
0.4 
0.09
0.8 
0.5 
*   Carbohydrate minus fiber 
** Added, refined sugars include sucrose, fructose, glucose or starch hydrolysates added during food    
manufacturing. 
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5.2.3 Micronutrient intake among patients and controls 
Micronutrient intake among patients and controls, dietary supplements 
included 
Table 7 shows values for micronutrient intake, including dietary supplements. There 
were no statistical significant differences when comparing the self-reported 
micronutrient intake between the patient group and control group. There was a trend 
toward a difference in tocopherol intake between the groups (mean intake of 10 
mg/day, SD = 5 in PCOS group and 14 mg/day, SD = 10 in the control group) but this 
did not achieve statistical significance (p = 0.08). 
Table 7 Micronutrient intake in PCOS and control group, dietary supplements 
included 
 
 
 
PCOS group (N=25) 
 
           Control group (N=24) 
 Mean      SD       Median     Q1        Q2 Mean    SD     Median     Q1       Q2   P-value 
Iron (mg) 
Folate (mcg) * 
Thiamin (mg) 
Riboflavin (mg) 
Vitamin A (mcg) 
Vitamin C (mg) 
Tocopherol (mg) 
Vitamin D (mcg) 
Calcium  (mg) 
12              6            10              9        12 
279          206          212           168     334 
1.5            0.7          1.3            1         1.8 
1.9            0.9           1.6          1.3        2.6 
1013         546          795         616     1252 
100           55            87            66       114 
10             5              9              7         15 
5.3             3.7        4.1           2.3          8.1 
867           237        857          729       1002           
12              5          11             9         15 
252           130       235          153      293 
1.4            0.6        1.3           0.9        1.6 
1.7            0.9         1.4          1.1         2.1 
1039        412       1027         653     1332 
113          59          101          71        154  
14            10           11            7          18 
6.5             5.2        4.8           2.1       9 
820            295       763        595        974 
0.7 
0.8 
0.7 
0.2 
0.4 
0.4 
0.08 
0.49 
0.34 
* corrected for cooking losses 
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The mean values for the reported intakes in both groups was within recommended 
limits for the most of the nutrients, except for iron, folate and vitamin D, where the 
mean values were below recommended limits for both groups (120).   
Micronutrient intake among patients and controls, dietary supplements 
not included 
Table 8 presents the values for self-reported micronutrient intake, with no dietary 
supplements included. There are no statistically significant differences when 
comparing nutrient intake between the two groups. Participants’ nutrient intake is less 
in accordance with NNR 2004 after excluding dietary supplements. We observed low 
intakes of folate and iron in both groups. Iron intake in PCOS group presented a mean 
value for the reported intake of 10 mg/day (SD=3). Vitamin D intake is also below 
recommended levels (120).  
Table 8 Micronutrient intake in PCOS and control group, dietary supplements not 
included 
 
 
 
PCOS group (N=25) 
 
           Control group (N=24) 
 Mean      SD       Median     Q1        Q2 Mean    SD     Median     Q1       Q2   P-value 
Iron (mg) 
Folate (mcg) * 
Thiamin (mg) 
Riboflavin (mg) 
Vitamin A (mcg) 
Vitamin C (mg) 
Tocopherol (mg) 
Vitamin D (mcg) 
10             3            10             9            11 
176          39          185            148       209 
1.1          0.2          1.1             0.9         1.3 
1.5          0.4          1.4           1.2           1.6 
878        417          715            595      1036 
89           40            78              65         108 
8             3                7               6            9 
3.7         2.2        3.9              2.1       5.2 
11              3         11             9        13 
187          60        190          137       236 
1.1          0.3         1.2         0.8          1.5  
1.5         0.6          1.2         1.1        1.8 
859        327          813        578     1196 
93           41           81           61       133 
9             4             7             6          10 
4.4         3.7        3.3         1.7          6.1 
0.51 
0.45 
0.60 
0.31 
0.74 
0.69 
0.72 
0.9 
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Calcium  (mg) 864       297        763           729       1002 816         296.8      763        594        974 0.34 
*corrected for cooking losses 
 
5.2.4 Proportion of subjects in the project not eating within 
recommended limits (NNR 2004) 
Macronutrient intake 
In table 9 we show proportion of subjects that were not eating within recommended 
limits, according to NNR 2004. All (100 %) of each group ate too little dietary fiber, 
and 24 % (n = 6) in the PCOS group and 38 % (n = 9) in the control group ate too 
much added sugar. We found that 92 % (n = 23) from the patient group and 83 % (n = 
20) from the control group, reported a diet high in total fats (i.e. > 30E %/day). 
Moreover, 96 % (n = 24) from the patient group and 100 % (n = 25) of the healthy 
women reported a diet with too much saturated fat intake compared to the 
recommended levels in NNR 2004.  
Table 9 Proportion of participants not eating within recommended limits, 
macronutrient intake 
         PCOS group 
N=25 
Control group 
N=24 
 %                                  N %                                    N 
Low dietary fiber (<3g/MJ/day) 100                                      25 100                                24 
High added sugars, (>10E%/day) 24                                         6 38                                   9 
Low in carbohydrates, 
(<50E%/day) 
88                                        22 79                                  19 
High in carbohydrates, 
(>60E%/day) 
0                                            0 0                                       0 
 56 
High in total fats, (>30E%/day) 92                                         23 83                                    20 
Higher in total fats, 
(>35E%/day) 
56                                        14 63                                    15 
High in saturated fat, 
(>10E%/day) 
96                                          24 100                                 24 
High in PUFA (>10E%/day) 8                                              2 4                                      1 
Low in protein (<15E%/day)* 20                                         5                                     21            5                                           
High in protein (>20E%/day) 12                                           3 8                                      2 
* Low protein was set at a level that lies within the recommended level according to NNR. A level of protein intake less than 10E%, 
which would below recommended level, it’s difficult to find in the Norwegian population. A national dietary survey showed that a level 
below 10E% is found among few Norwegian women, thus the ‘low protein’ intake was defined to 15E% or lower.  
 
Micronutrient intake 
Micronutrient intake, dietary supplements included 
Table 10 shows proportion of participants from each group with a dietary intake that 
is not in accordance with NNR 2004. Contributions to intakes of vitamins and 
minerals from supplements are included. 
We observed that most of the participants reported a diet poor in iron, B vitamins, and 
vitamin D.  For example, 84 % (n = 21) from the patient group and 75 % (n = 18) 
from the healthy women group ate a diet with iron content below recommended 
levels. Twenty one women from each group (i.e. 84 % from the PCOS group and 88 
% from the control group) ate too little folate compared to the recommended levels in 
NNR 2004. The majority of the participants had also calcium and vitamin D intake 
below recommendations. 
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Table 10 Proportion of participants not eating recommended limits; micronutrient 
intake, dietary supplements are included 
         PCOS group 
N=25 
Control group 
N=24 
 %                                          N %                                          N 
Low iron (<15mg/day) 84                                          21 75                                          18 
Low folate (<400mcg/day) 84                                          21 88                                           21 
Low thiamin  ( < 1.1g/day) 28                                            7 25                                            6 
Lower thiamin  (< 0.05 mg/ MJ) 100                                         25 100                                        24 
Low riboflavin (<1.3mg/day) 32                                             8 46                                          11 
Low vitamin A (<700mcg/day) 44                                          11 25                                           6 
Lower vitamin A intake 
(<400mcg/day) 
 0                                             0   0                                           0 
Low vitamin C intake 
(<75mg/day) 
36                                            9 25                                           6 
Low tocopherol (<8 mg/day) 36                                            9 25                                           6 
Low vitamin D (<7,5mcg/day) 76                                            19 67                                        16 
Low calcium (<800mg/day) 40                                            10 54                                        13 
 
Micronutrient intake, dietary supplements not included 
Participants’ nutrient intake is, as expected, less in accordance with recommendations 
after excluding dietary supplements. Table 11 shows proportion of subjects that 
reported a diet with vitamins and minerals content below recommended levels (120). 
All the participants had a folate intake below recommended level and 96 % (n = 24) 
from the PCOS patient and 88 % (n = 21) of healthy women reported a diet with iron 
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values below recommendations. Over half part of the patients 56%, (n = 14) and half 
part of the controls 50%, (n = 12) ate less tocopherol than recommended. Vitamin D 
intake was below recommendations in most of the participants, as well.  
Table 11 Proportion of participants not eating within recommended limits; 
micronutrient intake, dietary supplements not included 
         PCOS group 
N=25 
Control group 
N=24 
 %                                          N %                                          N 
Low iron (<15mg/day) 96                                          24 88                                          21 
Low folate (<400mcg/day) 100                                        25 100                                        24 
Low thiamin  ( < 1.1g/day) 44                                          11 33                                           8 
Lower thiamin  (< 0.05 mg/ MJ) 100                                        25 100                                        24 
Low riboflavin (<1.3mg/day) 36                                            9 54                                          13 
Low vitamin A (<700mcg/day) 48                                          12 38                                            9 
Lower vitamin A intake 
(<400mcg/day) 
0                                              0 4                                              1 
Low vitamin C intake 
(<75mg/day) 
40                                          10 42                                          10 
Low tocopherol (<8 mg/day) 56                                          14 50                                           12 
Low vitamin D (<7,5mcg/day) 96                                          24 79                                          19 
Low calcium (<800mg/day) 44                                          11 54                                          13 
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5.3 Plasma vitamins, antioxidants and iron 
Plasma levels of folate, cobalamins, antioxidant vitamins and carotenoids and serum 
ferritin were measured in all forty nine participants. One patient was diagnosed with 
celiac disease after we collected the blood samples; therefore she was excluded from 
these analyses.  
5.3.1 Plasma micronutrient levels, comparing the groups 
We found no statistical significant differences when comparing plasma antioxidant 
concentrations between the patient and control group, nor when comparing the other 
measured plasma micronutrient levels. Previous studies showed that serum alpha- and 
beta- tocopherol concentrations are strongly correlated with serum cholesterol. In 
addition there was demonstrated an association with triacylglycerol and between 
serum triacylglycerol and central obesity concentrations (121). In order to eliminate a 
possible confounding effect by cholesterol and triglycerider on serum levels of these 
antioxidants, alpha- and gama-tocopherol levels were corrected for cholesterol and 
triglycerider before statistical analysis.  
The results are presented as mean, SD, median and 25, 75 percentiles.  
Table 12 Serum ferritin, folate and cobalamins in PCOS and control group 
 
 
 
PCOS group (N=25) 
 
           Control group 2 (N=24) 
 Mean      SD         Median     Q1       Q2 Mean    SD     Median     Q1       Q2   P-value 
Folate 
Cobalamins 
Serum ferritin 
17             9              14            11        20 
324.8       175.7       288          212.7  374.2 
66.2         46.6         46.5          31.2     97.7 
15             5          14            12         17 
384.4       253.4    303        258       452.7 
62.2         45.4       47          31.5      94.5 
0.7 
0.2 
0.8 
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Table 13 Plasma antioxidant levels in PCOS group and control group 
 
 
 
PCOS group (N=25) 
 
           Control group (N=24) 
 Mean      SD         Median     Q1       Q2 Mean    SD    Median     Q1       Q2   P-value 
Retinol 
Lycopene 
Xantophyll 
Beta carorotene 
Alpha tocopherol *  
Gamma tocopherol * 
Vitamin C 
2.7            0.5          2.6             2.4     3.1 
0.8            0.3          0.7             0.6     0.9 
0.3           0.1           0.3             0.2      0.4 
0.8           0.5           0.6             0.3      1.1 
4.2           1.2           4.4             3.7      4.8 
0.3           0.2           0.3             0.2      0.4 
73           28.6          71.2           48.8     93 
2.6            0.4       2.6          2.3      2.9 
0.7            0.3       0.6          0.5      0.8 
0.3            0.1       0.3          0.3      0.4      
0.9            1.0       0.6          0.4      1.0 
4.7            1.1       4.7         3.9        5.2 
0.4            0.1       0.3         0.3      0.5 
66.6         23.2        66.0      49.1      86.4 
0.4 
0.2 
0.9 
0.7 
0.2 
0.4 
0.4 
   * corrected for cholesterol and triglyceride 
5.3.2 Predictors of plasma antioxidant levels in the PCOS and  
control group  
Correlations between obesity measures (e.g. body mass index, waist circumference 
and waist to hip ratio) and plasma antioxidant levels were conducted in the entire 
population sample and then separately in the patient and control group.  
The relationships between the different antioxidants and various variables in the 
entire population sample are shown as correlations factor Pearson, adjusted 
correlation and p-value. The present study indicated different associations between 
different antioxidant levels and obesity measures. Apart from waist to hip ratio, the 
other obesity measures were significant related to different antioxidant levels, before 
and after adjustment for the potential confounders. Most of the correlations were 
stronger in the PCOS women, compared to their BMI-matched controls.   
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Predictors of plasma retinol and carotenoid levels 
Predictors of plasma retinol and carotenoid levels are shown in table 14. We found 
that waist circumference (r=-0.31) and BMI (r=-0.30) are significant predictors of 
serum lycopene levels in the entire population sample. Waist circumference (r=-0.49) 
and BMI (r=-0.45) showed significant negative correlations with beta-carotene levels, 
independent of other considered disturbing factors.  
Table 14 Predictors of plasma retinol and carotenoid levels 
 
                       N=48 
Variable Unadjusted 
correlation 
p-value Adjusted 
correlation* 
p-value 
Age 0.12 0.4 0.09 0.5 
Smoking 0.23 0.1 0.22 0.1 
BMI 0.03 0.8 -0.01 0.9 
Age 0.12 0.4 0.07 0.6 
Smoking 0.23 0.1 0.22 0.1 
Waist 0.13 0.3 0.10 0.4 
Age 0.12 0.4 0.08 0.5 
Smoking 0.23 0.1 0.22 0.1 
 
 
 
Retinol 
Waist to 
hip ratio 
0.22 0.1 0.21 0.1 
Age -0.11 0.4 -0.06 0.6 
Smoking 0.09 0.5 0.12 0.4 
BMI -0.32 0.02 -0.31 0.03 
Age -0.11 0.4 -0.05 0.6 
 
 
 
Lycopene 
Smoking 0.09 0.5 0.11 0.4 
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Waist -0.32 0.02 -0.30 0.04 
Age -0.11 0.4 -0.12 0.4 
Smoking 0.09 0.5 0.10 0.4 
 
 
 
 
Waist to 
hip ratio 
0.18 0.2 -0.18 0.2 
Age 0.25 0.07 0.36 0.07 
Smoking -0.03 0.8 -0.03 0.7 
BMI -0.41 0.04 -0.49 0.000 
Age 0.25 0.07 0.36 0.008 
Smoking -0.03 0.8 -0.05 0.6 
Waist -0.37 0.009 -0.45 0.001 
Age 0.25 0.07 0.27 0.06 
Smoking -0.03 0.8 -0.06 0.6 
     
 
 
 
 
Beta -
carotene 
Waist to 
hip ratio 
-0.2 0.2 -0.22 0.1 
Age -0.02 0.8 0.09 0.4 
Smoking -0.18 0.2 -0.15 0.2 
BMI -0.46 0.001 -0.46 0.001 
Age -0.02 0.8 0.10 0.4 
Smoking -0.18 0.2 -0.17 0.2 
Waist -0.46 0.001 -0.48 0.001 
Age -0.02 0.8 0.009 0.9 
Smoking -0.18 0.2 -0.18 0.2 
 
 
 
 
Xanthophyll 
Waist to 
hip ratio 
-0.26 0.06 -0.26 0.07 
 * corrected for the other variables from the table.  
 63 
Predictors of plasma vitamin C levels  
Predictors of plasma vitamin C levels are shown in table 15. 
Waist circumference (r=-0.45) and BMI (r=-0.43) were significantly correlated with 
plasma vitamin C concentrations.  
Table 15 Predictors of plasma vitamin C levels 
 
                       N=48 
Variable unadjusted 
correlation 
p-value Adjusted 
correlation* 
p-value 
Age -0.10 0.5 0.01 0.9 
Smoking -0.21 0.2 -0.17 0.2 
BMI -0.46 0.001 -0.45 0.001 
Age -0.10 0.5 0.01 0.9 
Smoking -0.21 0.2 -0.19 0.2 
Waist -0.43 0.002 -0.43 0.003 
Age -0.10 0.5 -0.07 0.6 
Smoking -0.21 0.2 -0.19 0.2 
 
 
 
Vitamin C 
Waist to 
hip ratio 
-0.19 0.2 -0.18 0.2 
* corrected for the other variables from the table.  
Furthermore, when analyzing correlations in the two groups, results from linear 
multiple regressions showed that BMI and waist circumference were stronger 
predictors of vitamin C levels in the control group compared with the PCOS group 
(results not shown).  
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Predictors of plasma alpha- og gamma tocopherol levels 
Predictors of plasma alpha- and gamma-tocopherol levels in the entire population 
sample are shown in table 16. We found that body mass index (r=-0.31) and waist 
circumference (r=-0.35) were significant predictors of plasma alpha-tocopherol levels 
and their influence on alpha-tocopherol concentration were equally strong.   
Table 16 Predictors of plasma alpha- and gamma-tocopherol levels 
 
                       N=48 
Variable Unadjusted 
correlation 
p-value Adjusted 
correlation* 
p- value 
Age 0.19 0.2 0.26 0.07 
Smoking 0.02 0.9 0.02 0.9 
BMI -0.25 0.07 -0.31 0.03 
Age 0.19 0.2 0.27 0.05 
Smoking 0.02 0.9 0.003 0.9 
Waist -0.28 0.04 -0.35 0.01 
Age 0.19 0.2 0.2 0.2 
Smoking 0.02 0.9 0.00 0.9 
 
 
 
Alpha-  
tocopherol 
Waist to 
hip ratio 
-0.14 0.3 -0.15 0.3 
Age 0.1 0.4 0.08 0.6 
Smoking -0.06 0.6 -0.09 0.5 
BMI 0.18 0.2 0.17 0.2 
Age 0.1 0.4 0.08 0.6 
Smoking -0.06 0.6 -0.08 0.6 
 
 
 
Gamma- 
tocopherol 
Waist 0.16 0.2 0.14 0.3 
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Age 0.1 0.4 0.10 0.4 
Smoking -0.06 0.6 -0.08 0.6 
 
 
 
 
Waist to 
hip ratio 
0.17 0.2 0.17 0.2 
* corrected for the other variables from the table.  
When analyzing the groups separately, no statistical significant correlations were 
found with plasma gamma-tocopherol, nor with alpha-tocopherol levels, except for a 
significant association of alpha tocopherol with waist circumference in the control 
group after correcting for possible cofounders (r=-0.43, p=0.04).  
 
5.4 Binge Eating Score and Three Factor Eating 
Questionnaire 
Patients with polycystic ovary syndrome showed higher BES and TFEQ scores, but 
the differences between the PCOS and the healthy women group were not statistical 
significant. The most representative difference between the groups was when 
investigated the emotional eating scale, but we could not demonstrate significant 
difference (p=0.09).   
In table 17 we show the values for the BES and TFEQ scores in the patient and 
control group. The results are presented as mean, SD, median and 25, 75 percentiles.  
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Table 17 BES and TFEQ scores 
 
 
 
PCOS group (N=25) 
 
           Control group (N=24) 
 Mean      SD       Median     Q1        Q2 Mean    SD     Median     Q1       Q2   P-value 
BES score 
TFEQ score: 
      UE scale* 
     CR scale** 
     EE scale*** 
10.8          7.8       10.00        4.00      16.00 
 
44.5        20.8      44.44        29.6         57.4    
44.6        20.5      44.44        30.5         61.1      
42.8        26.7      44.44        25.0         63.8 
8.7            5.6      8.00         5.2        10.7 
 
38.5         15.6     37.04       26.8       50.9 
40.5         19.2     38.8         27.7       55.5 
30.7         23.1     27.7         12.5       54.1 
0.4 
 
0.2 
0.4 
0.09 
* Uncontrolled eating 
** Cognitive restraint 
*** Emotional eating 
Proportion of subjects characterized as non bingers, moderate or severe bingers, 
according to BES score, are shown in table 18.  
Table 18 Classification according to BES score   
         PCOS group 
N=25 
Control group 
N=24 
 %                                          N %                                          N 
Non bingers 80                                         20 92                                         22 
Moderate bingers 16                                         4 8                                            2 
Severe bingers 4                                           1 0                                            0 
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Correlations of BMI with BES and TFEQ scores in both groups are shown in table 19. 
A strong positive correlation for BES scores and the BMI was observed with 
univariate analysis in both our patients (r=0.50) and controls (r=0.53).  
We demonstrated also a medium strong correlation between BMI and emotional 
eating scale in the PCOS group (r=0.46, p=0.02) and a stronger correlation was found 
between these two variables among controls (r=0.72, p=0.000).  
Table 19 Correlations of BMI with BES and TFEQ scores 
 
 
 
Group  1 (N=25) 
 
Group  2 (N=24) 
           BMI            BMI 
 
r                    p-value r                    p-value 
BES score 0.50                0.009 0.53                0.008 
TFEQ score: 
     UE scale 
     CR scale 
     EE scale 
 
0.20                0.33 
0.19                0.35 
0.46                0.02 
    
0.13                      0.52 
-0.09                     0.65 
0.72                      0.00 
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6. DISCUSSION 
Analyses of this data showed no statistical significant difference in macro- and 
micronutrient intake between the PCOS and control group. Both groups reported a 
diet with a high energy from saturated fat and low content of fiber, certain vitamins 
(e.g. folate, thiamine, riboflavin and vitamin D) and iron.  
We found no statistical significant difference in micronutrient plasma levels between 
the two groups. We demonstrated that both BMI and waist circumference are 
significant negative predictors for plasma concentrations of several antioxidants such 
as lycopene, xanthophyll, beta-carotene and vitamin C. Our results showed also a 
positive correlation between waist circumference and BMI and serum ferritin levels in 
the PCOS group but not in their BMI-matched controls.  
According to our data, PCOS patients reported a higher BES and TFEQ scores 
compared to the controls, but this difference did not reach statistical significance. We 
noted also that participants with a higher degree of overweight presented higher BES 
and TFEQ scores.   
6.1 General methodological considerations 
6.1.1 Study population 
All the participants in the project were recruited through Stavanger University 
Hospital.  
This master thesis is a pilot study with a small number of participants, which could 
give insufficient statistical power. Thus, it is difficult to come to definite conclusions 
about diet in the PCOS.  We included 25 patients in the PCOS group and planned to 
include the same number participants in the control group. We managed to recruit 24 
controls. More time and resources to plan and recruit a larger number of participants 
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in the PCOS and control group, could give more statistical power and the results 
could be of more clinical importance. In addition, several statistical analyses were 
conducted on correlations between plasma antioxidants levels and obesity measures, 
and this could influence our results.  
6.2 Dietary intake 
Analyses of this thesis showed that there is no significant statistical difference at 0.05 
- level when comparing the self reported energy, macro- and micronutrient intake 
between the patient and control group. We were surprised to observe that both groups 
reported a diet with an energy content that did not meet their needs and, at the same 
time, was high in saturated fat and poor in vitamins and minerals.  
6.2.1 Methodological limitations of the dietary method 
Recruitment period 
We began recruiting the PCOS group in the month of September 2007 and we 
interviewed the first patients in the month of October. Those patients began to 
complete the food diary already that month. Because we planned to include BMI 
matched controls, we could not begin recruiting the control group before after we had 
recruited most of the patients. It could have been better if we had the possibility to 
recruit both groups at the same time. In that way the participants from the two groups 
could complete the food diary during the same time period.    
Methods of dietary assessment 
We did not record participants physical activity level (PAL) during the registration 
period. If we had been doing that we could than get a more representative picture of 
the energy needs and energy expenditure for every participant, and at the group level.   
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As a dietary assessment, seven days pre-coded food diary was chosen as the best 
available way to collect dietary data from the participants. It is possible that other 
dietary assessment methods would have provided a more accurate report of the food 
intake. It is possible that traditional method like the weighted record could reflect the 
true intake more accurate than the method we used. In addition it may be a level of 
inaccuracy when coding the food items/dishes that were written on the open spaces in 
the food diary, but one must note that the traditional weighted method has this 
disadvantage too.  
Compared to food frequencies questionnaire and a 24 hour recall, a pre-coded food 
diary requires more work from the participants and nutritionist than a food 
frequencies questionnaire and a 24 hour recall but it also gives a better estimate of the 
nutrient intake of the participants. Anyway, dietary analyses were limited o the 
contents of the nutrition database.  
However, the advantage of the pre-coded food diary method is that it is less time – 
consuming for the participants and researchers to conduct. Data from focus group 
interviews including adolescents showed that the daily time needed to complete the 
food diary was 10-15 minutes, which can be considered as acceptable (107).    
Along with the food diary the participants received a portion size booklet. A study 
conducted among adolescents showed that a large variability may exist in an 
individual level when choosing a photograph that correctly depicts a food portion 
size, but the error at the group level is quite small (107).   
Overall, in order to give the best possible data to our study it was important to choose 
this dietary assessment method because it gives a very good estimate of the food 
intake from our participants and, at the same time, is little time-consuming and easy to 
fill inn.    
 71 
Under-reporting 
Under-reporting food intake is a well known phenomenon in dietary surveys and is 
caused by a variety of factors (122). Under- reporting can be divided in two subtypes: 
“Under-eating” and “under-registration”. When subjects “under-eat”, they eat less 
than they normally do due to the fact that they are conscious of what they are eating 
when reporting. When subjects are “under-registering”, they omit reporting what they 
actually are consuming.  
Energy intake divided by basal metabolic rate will give an estimate whether or not 
subjects are having an EI that is consistent with life over time. Under-reporters are 
subjects with values EI:BMR<1.35, whereas <1.14 is not consistent with life (119). 
We calculated basal metabolic rate for every participant by using a regression 
equation based on age, sex and body weight (123). Accordingly, 100% of the patients 
(n = 25) and 80 % of the controls (n= 19) were under-reporters. Moreover, there were 
64% of the patients (n = 16) and 58 % of the controls (n= 14) that had values of EI : 
BMR < 1.14, aspects that could influence our final results.  
 
6.2.2 Discussion of dietary results 
The main objective of the current study was to examine whether women with PCOS 
consume a diet higher in total energy; fat and lower in vitamins, minerals and fiber, 
compared to a healthy control group. Based on recommendations for macro- and 
micronutrient intake for general populations and relevant findings in the literature 
regarding diet, PCOS and other lifestyle diseases, we gathered and discussed the 
nutritional factors that seem to play an important role in PCOS.  
Energy and nutrient intake 
Analyses of this thesis showed that there is no significant statistical difference at 0.05 
- level when comparing the self reported energy and macronutrient intake between the 
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patient and control group (p=0.38). The patient group reported a diet with saturated, 
mono- and polyunsaturated content similar to the diet reported by the control group.  
All the women participating in the PCOS study have good protein intakes at levels 
thought to be sufficient to meet the needs according to the Nordic recommendation 
for the general population (10-20 E %). Our results showed that there was no 
significant statistical difference when comparing protein intake between the groups (p 
= 0.5), nor when comparing carbohydrate intake (p = 0.4). The lack of statistical 
difference between the groups could be explained by the small sample size and 
measurement error. In addition there were subjects that were taking oral 
contraceptives which could affect their appetite and food choices.  
Comparing our data with results from other studies 
There are few studies that investigated diet in PCOS patients. Douglas CC et al. 
studied dietary intake in a group of thirty PCOS women, compared to a group of 
twenty seven healthy women. Similar to our findings, they demonstrated that women 
from PCOS group consumed a diet that was similar in total energy and macronutrient 
content to that of age-, race-, and BMI matched healthy women. In contrast to our 
results, they concluded that PCOS patients consumed more fat, especially trans fat 
but, that difference did not reach statistical power (64). Another study conducted by 
Wild et al. showed that PCOS women exhibited a diet higher in saturated fat than did 
age-matched control women (124). Moreover, a more recently study that compared 
two different ethnic, large populations, American and Italian PCOS women, 
concluded that the US group consumed significantly more saturated fat than did the 
Italian counterparts, despite having similar energy and macronutrient intake (125). We 
must note that all these studies used either a three day or four-day food diary, as a 
dietary assessment tool. Therefore, it is possible that our results are more 
representative because we used a seven-day food diary that included weekend days, 
which could be of importance when conducting a dietary survey.  
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We hypothesized that reported intake of dietary fiber would be significantly lower in 
women with PCOS compared with age-, and BMI-matched control women. Our 
analyses showed that the difference between the groups was not statistical significant 
with a mean reported intake of 18 g/day in the patient group and 19 g/day in the 
control group, i.e. 0.02 g/MJ in both groups. These results are similar to those from 
the study conducted by Douglas et al. but in contrast with the results published by 
Wild et al. that concluded that the dietary fiber intake was lower in the PCOS group 
compared to age-matched control women (124).    
Concerning literature I could not find other studies were micronutrient intake in 
PCOS patients was investigated. We hypothesized that women with PCOS will have a 
diet with a lower content of vitamins and minerals compared to our healthy age- and 
BMI-matched women. Analyses of our data showed that there were no statistical 
significant differences when comparing the reported micronutrient intake between the 
groups. However, we found that a large proportion of the women in PCOS and 
control group are not eating within recommended levels stated in NNR 2004, aspects 
that are discussed later in this master thesis.  
 
Women not eating within recommended levels stated in NNR 2004 
The results from our analyses reveal that a large proportion of the women in PCOS 
and control group are not eating within recommended levels stated in NNR 2004.  
Energy intake 
When comparing the mean values for energy intake in our groups with the references 
values for energy intake for women in the same group of age, there are lower values 
for energy intake in our groups. The references values for energy intake in NNR are 
calculated for groups of women with two different physical activity levels. When we 
look at our results the mean values for reported intake in our groups were lower, 
regardless of activity level. The mean value for the reported energy intake in the 
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PCOS group and control group was 8.25 MJ/day and 8.69 MJ/day respectively. The 
reference values for energy intake for women age 18-30 and 31-60, with a sedentary 
work and limited physical activity in leisure time, are 9.4 MJ/day and 9.2 MJ/day 
respectively. We must emphasize that fiber was not included when we calculated 
energy content. In addition, the values we are referring to were calculated for 
individuals within the normal range (18.5-24.9) of body mass index (120), while our 
participants were both normal and overweight women.   
Our participant’s low energy intake could be explained either by a low physical 
activity level or by the fact that they under-reported their food intake, or both factors.  
 
Both excessive and insufficient energy intake in relation to requirements leads in the 
long term to negative consequences for health. A very low energy intake is defined as 
an energy intake below 6.5 MJ/day as a minimum daily energy intake necessary for 
providing adequate amounts of micronutrients from the diet, while an energy intake of 
6.5-8 MJ/day is considered a low energy intake. At a low energy intake there is an 
increased risk of an insufficient intake of micronutrients (120;126).  
Several studies suggested that normal weight women with PCOS have a lower total 
energy intake when compared to healthy normal weight women (127). Carmina et al. 
comments that obesity or overweight could be part of the disorder of PCOS and diet 
and lifestyle may modify the phenotype (125).   
We did not observe among our participants that normal weight PCOS women have a 
lower energy intake than their BMI-matched controls. The reported energy intake in 
normal weight PCOS women was actually higher, with a mean value of 9 MJ/day, 
compared to 8 MJ/day mean intake reported by the healthy normal weight women. 
However, the normal weight groups have a very small number of participants (six 
normal weight women in each group) to give sufficient statistical power. 
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A low energy intake can be related to a low body weight. When looking at our normal 
weight and overweight patient’s energy intake, we observed that their individual 
energy intake varied largely independent of their body weight (results not shown). 
However we must note that while in the control group the overweight women (n= 18) 
reported a mean energy intake higher than normal weight controls (n = 6), i.e. 9 MJ, 
respectively 8 MJ/day, the overweight PCOS (n = 19) had a mean energy intake that 
was alike the energy intake reported by the normal weight PCOS (n = 6), i.e. 8 MJ.  
Could this mean that our overweight patients are less physical active, thus they need 
less energy, or that they under-reported their energy intake? There is now evidence 
that overweight subjects underreport their energy intake (122) and according to our 
calculations, all our patients under-reported their energy intake.  
On the other hand, it is possible that our overweight patients are aware of the negative 
effects of overweight in PCOS and they consciously restraint their food intake.   
Or is that possible that there are two different types of hormonal state in PCOS with 
different consequences on body weight, regardless energy intake?  
Fat intake 
Our data showed that the diet reported by our study population had a relatively high 
fat content, especially saturated fat. The mean value for the total fat intake was above 
recommended value in both groups, i.e. 36 E% fat, whereas 16 E % from saturated fat 
in the patient group and 37 E%, whereas 15 E% from saturated fat in the control 
group. At individual level there were twenty three women in the PCOS and twenty 
women in the control group that had a total fat intake that exceeded 35E %. Most 
importantly, twenty four women from each group (i.e. 96% from the PCOS and 100% 
from the patient group) did not manage to limit their saturated fat intake below 
recommended level.  
However, the reported PUFA intake in our groups was within recommended levels, 
with a mean intake of 7 E% in both patient group and control group. An intake of 
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polyunsaturated fatty acids exceeding 10 E% is not recommended, because this may 
increase the risk of lipid peroxidation. There were just 8% (n = 2) in the patient group 
and 4% (n=1) in the control group that had a diet with a high PUFA content.  
Although there are studies that showed beneficial effects of high fat diets in PCOS 
(28), on the balance of evidence to date a diet low in saturated fat is recommended in 
women with polycystic ovary syndrome (128). Thus, women participating in this 
project should be strongly advised to decrease their saturated fat intake.  
Fiber intake 
Dietary fiber intake in our population had a reported mean value that was below 
recommended levels, i.e. 18g fiber/day in PCOS group and 19g fiber/day in the 
control group. Fiber intake varied among participants but, most importantly, very few 
(five patients and four controls) reached the minimum recommended level of 25 g 
fiber/day. Moreover, when adjusted for energy intake (g/MJ), none of them managed 
to reach recommended level of 3mg/MJ/day. These results could mean that our 
participants had a very low intake of foods naturally rich in dietary fiber such as 
wholegrain cereals, vegetables, fruits and berries.  
As we mentioned in the introduction part of this master thesis, the health benefits of 
dietary fiber in reducing the risk of chronic diseases have been well-established. 
Several lines of evidence suggest that dietary fiber may play a key role in diseases 
which PCOS patients are at risk of, thus an increasing in fiber intake should be 
strongly advised.  
Added sugar intake 
Added sugar intake in our population varied largely. Many of the women from both 
groups did not manage to limit their intake to the recommended levels. More 
importantly, most of the women did not exceed 20 E% from added sugar and there 
were no participants with a sugar intake that exceed 30 E%. Consequently, even 
though too many participants, especially from the control group, ate too much sugar 
(four controls exceed 20 E% from added sugar), few had very extreme levels. We 
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found that no participant from the patient group reported more than 20 E% from 
added sugar and there were only five of them that had over 10 E% from added sugar. 
During the personal interviews with the participants, the master student noted that 
PCOS patients were more interested and aware of the effects of simple carbohydrates 
intake, (i.e. sugar), than our healthy women. It is, though, possible that the patients 
were more careful regarding sugar intake. On the other hand it is possible that they 
under-reported it.  
However, there is now ample evidence that a diet high in added sugar is unhealthy 
contributing only with ‘empty- calories’ which dilute the quality of the diet (129). In 
addition it is well proved that a consumption of sugar-containing soft drinks is 
positively correlated with overweight and obesity (130). Accordingly, there is 
sufficient basis to assert that a reduced intake of added sugars is recommendable.  
Vitamins and minerals intake 
Women from both the patient and control group reported a mean intake of A, C, and 
E vitamin that were within recommended levels, when including dietary supplements.  
After excluding dietary supplements, the mean reported intake of vitamin E was 8 
mg/day in the PCOS group and 9 mg/day in the control group. However, the levels of 
antioxidant vitamins intake were still within recommended levels after correcting for 
cooking losses, except for vitamin E intake from the patient group. The vitamin E 
requirement is partly related to the PUFA intake, which is generally not a practical 
problem since most foods rich in PUFA also are rich in vitamin E. The relationship 
between vitamin E and PUFA intake is related to the general antioxidant effect of 
vitamin E and, according to NNR, a ratio of 0.6α- TE / g PUFA in adults would be 
sufficient (120). This means that at an average of 5 E% from PUFA an intake of 7 
mg/day vitamin E should be sufficient for women in fertile age. The reported PUFA 
intake in our patient and control group was 7 E%. Thus, vitamin E intake in our 
groups should be approximately 9 mg/day in order to satisfy the ratio between vitamin 
E and PUFA intake, as recommended by NNR.  
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When looking at the proportion of the patients and controls not eating within 
recommended limits when excluding dietary supplements, we noted that 40%, 
respectively 42% reported a vitamin C intake below recommended by NNR. Over half 
part of the patients and half part of the controls ate less tocopherol than 
recommended. There was also 48% in the PCOS group and 38% of the healthy 
women that reported an intake of vitamin A below daily recommended. 
 
Analyses of this thesis showed that most of the women from both groups did not 
manage to reach the recommended level for iron and folate intake, even when 
including dietary supplements. Although we did not find a significant statistical 
difference between the groups, both PCOS and control group reported a diet where 
the mean values for iron and folate were below recommended values. When 
excluding contribution from dietary supplements, we noted a reduction in iron intake 
from 12 to 10 mg/day in the patient and from 12 to 11 mg/day in the control group. 
There were also a high proportion of the women that had a low iron intake, i.e.  96% 
from the PCOS and 88% from the control group reported an iron intake below 
recommendations, after correcting for contribution from iron supplements.  
The mean values for folate intake were very low in both groups, especially after 
excluding folate supplements, when the patient group reported a mean intake of 176 
mcg/day and the healthy women had an intake of 187 mcg folate/day. However, one 
must note that folate values are presented after correction for cooking losses.  
Furthermore, our results show that it was a representative proportion of women from 
both groups that did not follow recommended level for folate intake. We found that 
21 women from each group (i.e. 84% from the PCOS and 88% from the control 
group) ate too little folate compared to the recommended levels, when including 
folate supplements. Moreover, after correcting for the contribution from folate 
supplements none of the participants managed to reach the recommended value by 
NNR.  
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Comparing the women from PCOS study with Norwegian women at 
fertile age (results from Norkost 1997) 
A national dietary survey from 1997 using food frequencies questionnaires (FFQ) 
shows that Norwegian women at the age of 20-29, 30-39 and 40 - 49 have a mean 
intake of 20, 21 and 21 g of dietary fiber/day respectively, 12 and 9.3 E%, 8.1E % 
added sugar, 12.0, 13, 12 E% from saturated fat, and 5.3, 5.6 and 5.5 E% PUFA 
(including both omega-3 and omega-6 fatty acids). It is not shown how large 
percentage of the studied group did not follow the recommended intakes (131). 
However, when looking at mean values in our PCOS population, the mean fiber 
intake is lower with a mean intake of 18 g/day, the added sugar intake is also lower 
with a mean value of 7 E %, but saturated fat and intake of PUFA is higher (mean 
intake 16 E%, respectively 7 E%) than in the general female population from 1997 
aged 20-39. On the other hand when comparing our control group with Norwegian 
fertile women, we observe that our population has a higher proportion of energy from 
added sugar (mean value 10 E%).  
Regarding iron intake, women from the PCOS study reported a higher mean value for 
iron intake, with a mean value of 12 mg iron / day while the dietary survey showed 
that Norwegian women at age of 20-29, 30-39 and 40-49 have a mean intake of 9.7, 
9.6, 9.6 mg iron/day respectively.  
These results could indicate that participants in this study have an unfavourable diet, 
and they may not be eating healthier than women of fertile age in the Norwegian 
population. Yet, one must note that our study is conducted among few participants 
and we must be aware of the time of difference between 1997 and 2007, which may 
change the picture.  
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6.3 Vitamins, iron and antioxidant vitamins   
Results of this master project showed no statistical significant difference in folate, 
cobalamins, iron or antioxidant vitamins levels when comparing PCOS women with 
healthy women. We found, however, higher levels of serum ferritin and positive 
correlations of serum ferritin and obesity measures in our patients, which could 
indicate a higher degree of inflammation and oxidative stress associated with 
polycystic ovary disease.  
Our analyses indicated different associations of waist circumference and body mass 
index with the different antioxidants, but no statistical significant association of waist 
to hip ratio with any of the antioxidants. 
6.3.1 Methodological limitations of biochemical measurements 
Some of our results could be limited because we did not use the most specific method 
for the assessment of vitamin B12 and folic acid status. The assay of methyl-malonic 
acid (MMA) is very specific (raised MMA always means impaired B12 status) but 
this method is, however, very expensive (123). For the determination of folate levels 
we measured folate level in serum. Red-cell folate, however, reflecting the average 
intake 120-day life of the red cells is a far superior index (123).   
6.3.2 Discussion of biochemical results 
Vitamin B12 and folic acid 
Women with PCOS have been shown to have lower vitamin B12 levels and higher 
homocystein levels due to metformin treatment (93). In addition, folic acid and B12 
are all co-factors in homocystein metabolism, thus we assumed that women with this 
disorder could present lower folic acid levels, as well.  
Our data showed lower vitamin B12 levels in the PCOS group (mean value 324.8 
umol/L) compared with the healthy women group (mean value 384.4 umol/L), but this 
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difference could not reach statistical significant level. On the other hand, we found 
higher folate levels in our patients (17.2 nmol/L) compared with our controls (14.7 
nmol/L), but again, we could not find a significant difference between the groups.  
These results could be explained either by differences in dietary intake, dietary 
supplement use or other factors. Lower vitamin B12 levels in the patient group could 
be explained by the effect metformin treatment, as reported by several other studies. 
However, several patients reported that they took vitamin B supplements and some of 
them took folic acid supplement due to reduced serum levels of folic acid. There were 
women from the control group as well, that were on B vitamins and folate 
supplements. Thus, it is very difficult to conclude which factor has an important role 
in determining the difference between the groups.  
Iron stores 
Our results showed that patients with polycystic ovary syndrome have higher serum 
ferritin levels, compared with their BMI-matched controls (mean value 66.2ug/L, 
62.2ug/L respectively), but this difference did not reach statistical significance 
(p=0.7). This could be explained the fact that we had to small population sample to 
give sufficient statistical power and. In addition, our population sample included both 
normal- and overweight women and this could influence the outcomes. Higher levels 
of serum ferritin in PCOS women could be related to chronic inflammation or could 
indicate that body iron stores are increased in these women in agreement with what 
has been published for other insulin-resistant conditions (91). Luque RM et al. 
suggested that insulin resistance and hyperinsulinism, and not the reduced menstrual 
losses secondary to from oligo- or amenorrhea, are responsible of the increased 
ferritin levels and body iron stores found in overweight and obese women with PCOS 
(91). 
Increased iron stores in the liver are postulated to induce liver-mediated insulin 
resistance, with reduced hepatic insulin extraction and hyperinsulinemia and reduced 
ability of insulin to suppress hepatic glucose production. Serum ferritin levels have 
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been found to be associated with decreased insulin sensitivity and increased fasting 
serum insulin and blood glucose. These abnormalities might lead to increased 
adiposity. In several studies, serum ferritin was correlated with insulin resistance 
syndrome (132), metabolic syndrome (90) and diabetes (133), all conditions women 
with PCOS are at risk of. Indeed, it has been reported previously that overweight and 
obese women with PCOS have increased serum ferritin levels (134) and it has been 
discussed that the increased body iron stores might contribute to the insulin resistance 
and beta-cell dysfunction frequently found in PCOS patients (91).  
Correlations of iron stores with obesity measures 
A strong positive correlation between waist circumference and BMI and serum 
ferritin levels was found in the PCOS group but not in their BMI-matched controls. 
Moreover, these two variables were equally strong predictors for serum ferritin 
concentrations in the PCOS women (r=0.57 for both variables). These observations 
could indicate a higher degree of oxidation stress associated with the PCOS and, in 
accordance with results from other studies, these women could be at higher risk for 
development of diabetes type 2 and cardiovascular disease, compared with the 
controls.  
Few studies have examined the relationship of body iron stores and indices of body 
fat distribution, despite the relationship postulated for both variables with coronary 
heart disease and ischemic stroke (135-137). However, like our data, results from two 
other studies showed a positive correlation between serum ferritin levels and various 
index of adiposity, such as BMI: data from a study that examined the association 
between serum ferritin levels and cardiovascular risk factors among Norwegian men 
reported independent associations of serum ferritin with waist-to-hip ratio and body 
mass index (138) and, Gillum et al reached similar conclusions in a study conducted 
among Mexican American men aged 20-49 years (139). On the other hand, in a small 
study of healthy Spanish volunteers, no association of serum ferritin with waist-to-hip 
ratio was found (132), results that are consistent with our findings.    
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Plasma antioxidant levels 
Comparing the groups 
Our data showed mean values of measured antioxidants vitamins that were lower in 
the patient group compared with their BMI matched controls, except for retinol, 
lycopene, and vitamin C. However, we failed to show a statistical significant 
difference in plasma antioxidant levels between the groups. It is possible that this is 
due to a too small population sample to give statistical power.  
The differences we observed, however, could be a result of dietary differences, 
increased oxidative stress or dietary supplements, impaired absorption, increased use, 
or other possible factors. We found no significant differences in vitamin intake 
between the groups, thus is more likely that the differences could be explained by 
oxidative stress, increased use and dietary supplements. Our healthy women, for 
instance, presented lower vitamin C concentrations compared with the PCOS women. 
It is possible that this result is primarily due to smoking habits and higher oxidative 
stress and it is plausible to discuss an increased use in of ascorbic acid (and other 
antioxidants) in smokers in order to scavenge free radicals. Anyway, other factors 
such as difference in dietary supplements and impaired absorption should be 
considered.  
Correlations between obesity measures and antioxidant plasma levels 
Results of this thesis showed different associations between different antioxidant 
levels and abdominal and general obesity as determined by waist circumference and 
BMI. We found no significant correlations between waist to hip ratio and measured 
serum levels of antioxidants. Our observations are presented below. 
Predictors of plasma carotenoid and retinol levels  
Results from the entire population 
We observed that serum beta carotene and xanthophyll levels correlated negatively 
with waist circumference and BMI before and after adjusting for confounding factors 
such as age and smoking. The correlations of abdominal and general obesity with 
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serum beta-carotene and xanthophyll levels were strong. These results could indicate 
that general and central obesity are more important determinants of serum carotenoid 
and xanthophyll levels compared to the other considered factors. Furthermore, BMI 
was an independent significant predictor of lycopene levels (r=-0.32), so was waist 
circumference. We could note small correlations between waist to hip ratio and 
plasma levels of measured carotenoids, but the correlations could not reach statistical 
significance.  
Results from each group 
Serum beta-carotene levels were negatively associated with general and central 
obesity in both groups, when controlling for confounding factors. Both the correlation 
with BMI and with waist circumference was strong. However, the association with 
both obesity measures was stronger in the patient group compared with the control 
group, after correcting for considered disturbing factors. This could indicate that 
obesity is a stronger determinant for beta-carotene levels in PCOS patients compared 
to other factors and, possible more than in the controls.  
Waist circumference (r=-0.55) and BMI (r=-0.56) were significantly associated with 
decreased serum levels of xanthophyll in patients with polycystic ovary syndrome, 
whereas it was just central obesity (r=-0.44), after controlling for disturbing factors in 
the control group. The correlation was, as shown above, not as strong as in the patient 
group. These observations could overall indicate that central obesity is a stronger 
predictor of xanthophyll levels compared to other considered factors, in both groups.  
On the other hand, when correcting for age and smoking in the patient group, waist 
circumference (r=-0.39) and BMI (r=-0.38) were still determinants of serum lycopene 
levels but not statistical significant, as before correcting for disturbing factors. Thus, 
the correlation PCOS patients presented in univariate analysis could be attributed to 
the interference of other non considered factors. 
No significant correlations between obesity measures and plasma retinol levels were 
found. We noted, however, that waist circumference (r=0.22) and BMI (r=0.18) were 
 85 
positively correlated with retinol in the patient group, whereas we noted a negative 
correlation with BMI (r=-0.2) and no correlation with waist (r=-0.05), in the control 
group. None of these correlations could reach statistical significance.  
Predictors of vitamin C plasma levels  
Results from the entire population 
Our results showed that waist circumference (r=-0.43) and BMI (r=-0.45) are strong, 
negative predictors of plasma vitamin C concentrations even after controlling for the 
potential cofounders, but no significant correlations were found in relation to waist to 
hip ratio. The oxidative stress associated with obesity and increased use of scavenging 
antioxidants could be consistent with our findings, lower vitamin C levels in women 
with higher degree of obesity.   
Results from each group 
We noted that our healthy women presented stronger association of obesity with 
plasma vitamin C levels compared with the PCOS patients, which showed no 
statistical significant correlations after adjustment for confounding factors. It is 
possible, thus, that the effect of obesity measures on plasma vitamin C levels is 
stronger than the effect of other factors in our control group but not in the patient 
group. Could this indicate that there are other factors, no considered here, that 
influence vitamin C levels in this group of PCOS patients?  
Predictors of gamma- and alpha-tocopherol plasma levels  
Results from the entire population 
No statistical significant correlations between any of the obesity measures and plasma 
levels of gamma-tocopherol were found. However, both waist circumference (r=-
0.35) and BMI (r=-0.31) were significant predictors of alpha-tocopherol levels after 
adjusting for confounding factors. Waist circumference correlated negatively with 
alpha-tocopherol concentrations (r=-0.28), before adjustment for confounding factors, 
as well.  
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Results from each group  
Our results showed that waist circumference is a negative, significant predictor of 
alpha - tocopherol levels after correcting for age and smoking, in the healthy women 
group (r=-0.43) but not in the patient group. We noted, anyway that the effect waist 
circumference had on alpha-tocopherol concentrations was actually not so different 
between the groups (a increasing in waist circumference by one centimetre could 
decrease serum alpha - tocopherol levels by 0.02 umol/l among the healthy women 
and by 0.017umol/l in the patient group).   
Our data compared with results from other studies 
Concerning literature I was not able to find other studies where correlations of obesity 
measures with plasma antioxidant concentrations were investigated in women with 
PCOS.  
Several studies showed, however, that women with PCOS have increased oxidative 
stress and that hyperinsulinemia resulting from insulin resistance is frequently 
associated with the disorder (140;141), which could give lower antioxidant status in 
this group of patients compared with age- and BMI-matched healthy women. As 
presented earlier, we found negative correlations between obesity measures and 
plasma antioxidant levels in this population. Lower plasma antioxidant levels in 
women with higher degree of obesity could be interpreted as high degree of oxidative 
stress, more pronounced inflammation and high use of antioxidants with increasing 
fat mass.    
In accordance with our results, most of the reports among females consistently 
showed that serum beta-carotene (53;54;142) and vitamin C (49) were negatively 
associated with BMI and other measures of obesity. A study conducted among both 
men and women demonstrated that abdominal adiposity is significantly and 
independently associated with decreased serum levels of several carotenoids in 
women (43). However, in an article published more recently it was shown that BMI is 
inversely associated with plasma concentration of carotenoids but not with plasma 
vitamin C in older women (51).  
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Virtanen et al. investigated correlations of antioxidant levels in adipose tissue and 
measures of obesity in both men and women. In women waist circumference was 
shown to be an independent negative predictor of alpha-carotene level, BMI was a 
predictor of beta-carotene, results that are consistent with our findings (50).  
It has been suggested that the independent negative association between general 
obesity and serum beta - carotene concentration might have at least two mechanisms. 
The first is that beta-carotene is distributed differently between plasma and adipose 
tissue, the former being the dominant storage tissue of beta-carotene in humans. 
Accordingly, a person with high fat mass would have a larger proportion of ingested 
beta-carotene absorbed by fat tissue than would a lean person if all other metabolic 
factors were equal. A second explanation could be that the estimates of beta-carotene 
intakes among obese individuals fail to detect a lower consumption of foods that 
would increase serum beta-carotene concentrations (44;143).  
Recently it was shown that BMI predicted even the evolution of serum carotenoids 
during a 7-year follow-up among young non-smoking adults with the exception of 
lycopene (144). Several other studies have also failed to observe associations between 
BMI and lycopene (53;145;146). These results are in contrast with our findings; we 
observed a significant correlation of BMI with plasma lycopene levels.     
Consistent with the results from this master thesis, previous studies reported a 
negative association between serum alpha-tocopherol and both general and central 
obesity (60;61). It was suggested that the part of the increased incidence of 
cardiovascular disease associated with central obesity may be caused by low alpha-
tocopherol status. Body mass index was shown to influence alpha-tocopherol 
concentrations in a group of non-smoking Mediterranean population (59) and, in like 
in our PCOS group, no associations were found in two other studies (55;62). 
However, the first study mentioned was conducted among younger and older 
participants (over 60 years) of both gender and the second was conducted among 
obese children. Thus, the comparison with our results is not optimal primarily because 
of participant’s different metabolic state that could influence the results. 
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No significant associations of gamma-tocopherol concentrations with obesity 
measures were found in women participating in this project, but it was positively 
associated with BMI in several other studies (53;54).    
 
Smoking, carotenoid and vitamin C levels 
In this study, smoking was not a significant predictor of different carotenoid levels 
and, particularly, no significant correlation was found between smoking and beta-
carotene concentrations (r<0.1) both unadjusted and adjusted for obesity measures 
and age. This could be explained by the fact that there were few smokers in our 
population, 9 (18.3%) participants reported that they were smokers. We found no 
correlation with smoking in the PCOS group and a small negative correlation in our 
healthy women, when adjusted for age and waist to hip ratio (the difference in beta 
carotene levels between healthy smokers and non smokers was 0.28 umol/L). 
Anyway, our analysis in the control group showed that smoking was a negative, 
medium strong predictor (r=-0.4) of plasma vitamin C levels when controlling for age 
and waist circumference. We found that the difference in plasma vitamin C levels 
between smokers and non-smokers is 21.2 umol/L. These results are in accordance 
with reports that indicated adverse effects of smoking on vitamin C metabolism and 
results that demonstrated lower vitamin C concentrations in smokers compared with 
non-smokers (63). 
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6.4 Binge Eating Score and Three Factor Eating 
Questionnaire  
Analysis of the data from this project showed higher BES and TFEQ scores in PCOS 
women compared with the controls, but the difference was not statistical significant. 
We observed that women with a higher degree of obesity were more likely to express 
binge eating episodes and emotional eating. All these aspects are discussed below. 
6.4.1 Methodological limitations of the questionnaires 
The BES score has been proposed as a screening tool for binge eating disease in 
obese. It was however proposed that the diagnosis binge eating should be confirmed 
by a clinical interview (147). A disturbing element when using self-reported 
questionnaires could be the subjectivity when answering the questions. For example, 
how much food is actually considered larger than normal amount of food?   
Compared to self-reported questionnaires, interviews could provide more accurate 
information and reliable diagnose, since the interviewer can define the terms and 
explain questions and help the participants remember. An interview is, however, more 
time consuming and needs to be performed by specifically trained personnel. 
6.4.2 Discussion of results on dietary behaviour 
Binge Eating Score 
According to our observations, PCOS patients showed a higher BES score compared 
to their BMI-matched controls (mean score 10.8 point in the PCOS, and 8.7 point in 
the control group) but the difference was not statistical significant (p=0.4).  
As in previous studies using BES, subjects scoring 17 or lower were classified as non 
bingers, those with scores of 18-26 as moderate bingers, and those scoring 27 or 
higher as severe bingers. Twenty (80%) women from the PCOS population and 22 
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(92 %) healthy women were classified as nonbingers. Moderate binge eating was 
diagnosed in four (16%) women in the polycystic ovary group and in two (8 %) 
women in the control group. One woman from the patient group reached a score of 
more than 27 and, accordingly, was diagnosed as severe binger. Thus, we observed 
that, compared to their BMI-matched controls, more than the double of women from 
the patient group experienced binge eating episodes. 
 
The term binge eating is a term introduced in 1959 to describe a problematic 
behaviour found in a subgroup of overweight individuals (148). Several research 
groups described a subset of obese patients who had episodes of binge eating in the 
absence of compensatory behaviours, distinctive clinical features and high levels of 
associated psychopathology.    
Research showed that women with PCOS are often diagnosed with eating disorders 
and, moreover, it was postulated that there is a correlation between ovarian 
morphology and bulimia. Changes in peripheral insulin sensitivity were proposed as 
the link between PCOS and bulimia (99). This study was, however, conducted on a 
small population sample, thus the clinical importance of their results could be 
questionable. 
Moreover, there were researchers that proposed another theory in order to explain the 
link between these two disorders. Fairburn et al. postulated that some symptoms of 
PCOS such as menstrual irregularity, hirsutism, acne and obesity, may contribute in 
development of disordered eating habits (149). In this master project we did not 
investigate the clinical features in the patients and we did not perform pelvic 
ultrasonography, thus we could not investigate possible associations of these factors 
with binge eating. We found, however, a higher BES score in the PCOS group 
compared to their BMI-matched controls. We could, though, assume that women with 
polycystic ovary disease could be at increased risk of binge eating, maybe due to 
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clinical signs such as weight gain, hirsutism and acne, in accordance with the theory 
proposed by Fairburn et al.   
Results from a study conducted recently, could not find any significant association 
between PCOS, or polycystic ovaries with binge eating disorder nor to support the 
hypothesis that polycystic ovaries predispose towards development of eating disorders 
(150). This study used eating disorder examination (EDE) as assessment tool, an 
interviewer-based questionnaire, which is considered “gold standard” diagnostic tool 
for assessment of eating disorders, and thus the results could be more conclusive.        
Three Factor Eating Questionnaire 
The PCOS patients presented higher scores on all three TFEQ-R21 scales compared 
to the controls but we could not demonstrate a statistical significant difference 
between the groups. These results could, however, indicate that women with 
polycystic ovary syndrome express a more uncontrolled, restraint and emotional 
eating. This means that women with this disorder are more likely to lose control over 
eating and have higher tendency to restraint their food intake in order to control body 
weight. Especially the emotional eating scale score was higher in our patients 
compared to controls. Even when we could not demonstrate a significant higher 
emotional eating scale, a higher score in our patients could indicate that this group of 
patients is at a higher risk of overeat in relation to negative mood states. This 
observation is in accordance with the higher BES scores in women with PCOS that 
places these women at higher risk of developing binge eating.   
Correlations of BMI with BES and TFEQ scores 
A strong positive correlation for BES scores and the BMI was observed with 
univariate analysis in both our patients (r=0.50) and controls (r=0.53). Accordingly, 
when analyzing correlations between TFEQ scales scores an BMI, we found a strong 
correlation between emotional eating scale and body mass index. Indeed, these results 
could indicate that participants with a higher degree of overweight are more likely to 
engage in binge eating behaviour, as previously reported by other studies (151) and to 
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overeat in relation to negative mood states. Or is it possible that these women are 
overweight because they are bingers or emotional eaters? In accordance with our 
findings, BMI was positively correlated with all three TFEQ-R18 factors, a revised 
the instrument to an 18-item questionnaire based on the original items in a study 
conducted recently (152). Moreover, the correlation between emotional eating and 
BMI it was shown to be higher in overweight than in normal-weight subjects (153).   
It was suggested that specific eating behaviours may contribute to weight gain 
through an increase in food intake (154). However, the causal relation between these 
two variables remains unclear. Further studies are needed to find out whether the 
weight gain leads to emotional eating or whether persons with a tendency toward 
emotional eating gain weight more easily than do others. 
Further, we found of interest to analyze the relationship of binge eating behaviour 
with uncontrolled eating and emotional eating in our groups. Strong correlations of 
BES score with both uncontrolled and emotional eating scales were observed in both 
groups. According to these findings, women with problems in controlling food intake 
and in controlling eating in relation to emotions are more likely to engage in binge 
eating.  
 
Our results showed a higher BES score and TFEQ scale scores in PCOS patients 
compared with the healthy women, the difference was not statistical significant, 
possible due to small population sample. Therefore, these results could be of 
questionable clinical significance. One must note, however, that our observations are 
in accordance with results from several other studies, regardless of the assessment 
tool that was used.   
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7. Conclusion  
Results of this master thesis showed that the women with PCOS had similar diets to 
controls and the majority of women from both groups reported an unbalanced diet that 
is not within recommended guidelines. Saturated fat from fatty diary products, minced 
meat and meat products, added sugar from soft drinks, sweets and chocolates, and low 
intakes of important micronutrients contribute strongly to an unhealthy diet, and were 
observed in both groups. Women from both groups underreported their food intake. 
When matched for BMI, women with PCOS had similar antioxidant blood levels as 
well as eating behaviour to controls. However, increased BMI was associated with 
emotional eating and binge eating as well as with low levels of several antioxidants.  
These observations could indicate that specific dietary interventions may not be 
needed for women with PCOS. However, a balanced diet within the present 
recommended levels, rich in mixed greens, whole grains cereals, fat reduced diary 
products, fish, and lean meats should be consumed, whereas intake of soft drinks, 
sweets and chocolates, minced meat and meat products should be limited. Extra 
attention should be given to those with a BMI not within the normal range.  
Knowledge of how to advice and reach out to this population with the right 
information is a challenge, and must be focused on. The importance of an adequate 
diet in attention of the negative health outcomes women with PCOS are at risk of 
seems evident. The importance of life style factors, including diet, in managing this 
disorder needs to be explored further in detail. More research is needed to confirm 
previous findings or add new information, so we can tailor advice to women with 
PCOS and women with BMI not within the normal range, and thus prevent negative 
health outcomes.  
A great effect may come from promoting the already existing recommendations. 
Thus, the question of how to influence women to change their diet and life style 
should be addressed. Clinical nutritionists and other health workers should guide 
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women with PCOS and women with BMI not within normal range, in how to achieve 
healthier life style. However, it is likely that giving information to these women is not 
enough. Well-designed interventions and studies of how to implement of how to 
implement the existing recommendations are most likely needed.   
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